

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 487/04, A61K 31/53 // (C07D 487/04, 253:00, 231:00)	A1	(11) International Publication Number: WO 94/19350 (43) International Publication Date: 1 September 1994 (01.09.94)
(21) International Application Number: PCT/JP94/00213 (22) International Filing Date: 9 February 1994 (09.02.94) (30) Priority Data: 9303993.1 26 February 1993 (26.02.93) GB (71) Applicant (for all designated States except US): FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541 (JP). (72) Inventors; and (75) Inventors/Applicants (for US only): KAWAI, Yoshio [JP/JP]; 3-33-14, Kamikashiwada, Ushiku-shi, Ibaraki 300-12 (JP). YAMAZAKI, Hitoshi [JP/JP]; 4-15-203, Tsuchida, Tsukuba-shi, Ibaraki 300-26 (JP). TANAKA, Hirokazu [JP/JP]; 3-10-21, Hanayashiki Souen, Takarazuka-shi, Hyogo 665 (JP). OKU, Teruo [JP/JP]; 8-2, Midorigaoka, Tsukuba-shi, Ibaraki 305 (JP). (74) Agent: SEKI, Hideo; Fujisawa Pharmaceutical Co., Ltd., Osaka Factory, 1-6, Kashima 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532 (JP).		(81) Designated States: AU, CA, CN, HU, JP, KR, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>

(54) Title: PYRAZOLITRIAZINES WITH INTERLEUKIN-1 AND TUMOUR NECROSIS FACTOR INHIBITORY ACTIVITY

(57) Abstract

New heterocyclic derivatives of formula (I) wherein R¹ is aryl which may have suitable substituent(s) or heterocyclic group which may have suitable substituent(s), R² is aryl which may have suitable substituent(s) or heterocyclic group which may have suitable substituent(s), R³ is hydrogen or acyl, R⁴ is hydrogen, lower alkyl, cyclo(lower)alkyl, cyclo(lower)alkyl-(lower)alkyl, carboxy(lower)alkyl, protected carboxy(lower)alkyl, ar(lower)alkyl which may have suitable substituent(s), ar(lower)alkenyl, bridged tricyclicalkyl, heterocyclic group which may have suitable substituent(s), acyl, or a group of formula (b) (in which A is lower alkylene), and R⁵ is hydrogen or lower alkyl, and a pharmaceutically acceptable salt thereof which are useful as interleukin-1 and tumor necrosis inhibitors.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

D E S C R I P T I O N

PYRAZOLITRIAZINES WITH INTERLEUKIN - 1 AND TUMOUR
NECROSIS FACTOR INHIBITORY ACTIVITY

5 TECHNICAL FIELD

This invention relates to new heterocyclic derivatives and pharmaceutically acceptable salts thereof which are useful as a medicament.

10

DISCLOSURE OF INVENTION

This invention relates to new heterocyclic derivatives. More particularly, this invention relates to
15 pyrazole derivatives and pharmaceutically acceptable salts thereof which have pharmacological activities, processes for preparation thereof, a pharmaceutical composition comprising the same and a use of the same.

Accordingly, one object of this invention is to
20 provide the new and useful pyrazole derivatives and pharmaceutically acceptable salts thereof which possess a strong inhibitory activity on the production of Interleukin-1 (IL-1) and a strong inhibitory activity on the production of tumor necrosis factor (TNF).

25 Another object of this invention is to provide processes for preparation of the pyrazole derivatives and salts thereof.


A further object of this invention is to provide a pharmaceutical composition comprising said pyrazole
30 derivatives or a pharmaceutically acceptable salt thereof.

35

- 2 -


Still further object of this invention is to provide a use of said pyrazole derivatives or a pharmaceutically acceptable salt thereof as a medicament for prophylactic and therapeutic treatment of IL-1 and TNF mediated diseases such as chronic inflammatory diseases, specific
 5 autoimmune diseases, sepsis-induced organ injury, and the like in human being and animals.

The object pyrazole derivatives of the present invention are novel and can be represented by the following general formula (I) :
 10



wherein R^1 is aryl which may have suitable substituent(s) or heterocyclic group which may have suitable substituent(s),
 20 R^2 is aryl which may have suitable substituent(s) or heterocyclic group which may have suitable substituent(s),
 25 R^3 is hydrogen or acyl,
 R^4 is hydrogen, lower alkyl, cyclo(lower)alkyl, cyclo(lower)alkyl-(lower)alkyl, carboxy(lower)alkyl, protected carboxy(lower)alkyl, ar(lower)alkyl which may have suitable substituent(s),
 30 ar(lower)alkenyl, bridged tricyclicalkyl, heterocyclic group which may have suitable substituent(s), acyl, or a group of the formula :

35




- 3 -

(in which A is lower alkylene), and
R⁵ is hydrogen or lower alkyl.

The object compound (I) of the present invention can
be prepared by the following processes.


Process (1)



(II)

or a salt thereof


Reduction



(Ia)

or a salt thereof


- 4 -

Process (2)

(Ib)


or a salt thereof

Acylation



(Ic)

or a salt thereof


Process (3)

(Id)

or a salt thereof


- 5 -

Reduction



(Ie)
or a salt thereof


Process (4)



(III)
or a salt thereof

reduction


- 6 -



or a salt thereof

10


Process (5)



or a salt thereof




Elimination reaction of the
hydroxy protective group



or a salt thereof


35

Process (6)

(Ii)


or a salt thereof

Elimination reaction of
the amino protective group



(Ij)



or a salt thereof

Process (7)

(Ik)

or a salt thereof

- 8 -



(II)

or a salt thereof

wherein R^1 , R^2 , R^3 and R^5 are each as defined above,

R_a^4 is acyl,

R_b^4 is acyl having protected hydroxy,

R_c^4 is acyl having hydroxy,

R_d^4 is acyl having protected amino,


R_e^4 is acyl having amino,

R_f^4 is acyl having a leaving group,

R_g^4 is acyl having N-containing heterocyclic group,


R^6 is hydrogen, C_1 - C_5 alkyl, cyclo(lower)alkyl, cyclo(lower)alkyl- $(C_1$ - C_5)alkyl, aryl which may have suitable substituent(s) or ar(C_1 - C_5)alkyl which may have suitable substituent(s),

a group of the formula :



cyclo(lower)alkyl-(lower)alkyl,
 carboxy(lower)alkyl, protected


carboxy(lower)alkyl, ar(lower)alkyl which
 may have suitable substituent(s),
 ar(lower)alkenyl, bridged tricyclicalkyl,
 heterocyclic group which may have suitable
 substituent(s),
 or a group of the formula :



(in which A is lower alkylene),
 X^{1-} is anion, and
 $-N$ is N-containing heterocyclic group.


The starting compounds or salts thereof can be
 prepared by the following Processes.

Process (A)



(V)


or a salt thereof



(VI)

or a salt thereof

- 10 -




5

(VII)

or a salt thereof

Process (B)

10



15

(VII)

or a salt thereof


20

 H_2NOH

(VIII)

or a salt thereof.

25




30

(IX)

or a salt thereof

35

Process (C)




(IX)

or a salt thereof




Cleavage reaction
of O-N bond



(X)

or a salt thereof

Process (D)




(X)

or a salt thereof



halogenation

- 12 -



(XI)


or a salt thereof

(2)

 H_2NNH_2


(XII)

or a salt thereof



(XIII)

or a salt thereof

Process (E)

(XIV)


or a salt thereof

 R^2-CH_2CN

(XV)

or a salt thereof

- 13 -




5

(X)

or a salt thereof

Process (F)

10




15

(X)

or a salt thereof


20



(XII)

or a salt thereof

25




30

(XIII)


or a salt thereof

35

Process (G)


(XIII)

or a salt thereof

↓
diazotization

(XVI)

or a salt thereof


Process (H)

(XVI)

or a salt thereof


35

- 15 -




(XVII)

or a salt thereof




(IIa)

or a salt thereof

Process (I)

(Ib)


or a salt thereof



(XVIII)

or a salt thereof

- 16 -



(III)

or a salt thereof

wherein R^1 , R^2 , R^5 , X^{1-} and $-\text{CH} \begin{matrix} \nearrow R^7 \\ \searrow R^8 \end{matrix}$ are each as

defined above,

R^9 and X^3 are each a leaving group,

X^2 is halogen,

R^{10} is lower alkyl,

R^{11} is lower alkyl or aryl, and

X^4 is acid residue.

Suitable pharmaceutically acceptable salts of the object compound (I) are conventional non-toxic salts and may include a salt with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt (e.g., sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.), an ammonium salt; a salt with an organic base, for example, an organic amine salt (e.g., triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.); an inorganic acid addition salt (e.g., hydrochloride, hydrobromide, sulfate, phosphate, etc.);

an organic carboxylic or sulfonic acid addition salt (e.g., formate, acetate, trifluoroacetate, maleate, tartrate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.);

5 a salt with a basic or acidic amino acid (e.g., arginine, aspartic acid, glutamic acid, etc.).

In the above and subsequent descriptions of the present specification, suitable examples and illustration of the various definitions which the present invention
10 intends to include within the scope thereof are explained in detail as follows.

The term "lower" is used to intend a group having 1 to 6 carbon atom(s), unless otherwise provided.

15 The term "higher" is used to intend a group having 7 to 20 carbon atoms, unless otherwise provided.

Suitable "lower alkyl" and "lower alkyl moiety" in the terms "cyclo(lower)alkyl-(lower)alkyl", "carboxy(lower)alkyl", "protected carboxy(lower)alkyl" and "ar(lower)alkyl" may include straight or branched one
20 having 1 to 6 carbon atoms(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, tert-pentyl, hexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, and the like.

Suitable "lower alkenyl moiety" in the term
25 "ar(lower)alkenyl" may include vinyl, 1-(or 2-)propenyl, 1-(or 2- or 3-)butenyl, 1-(or 2- or 3- or 4-)pentenyl, 1-(or 2- or 3- or 4- or 5-)hexenyl, methylvinyl, ethylvinyl, 1-(or 2- or 3-)methyl-1-(or 2-)propenyl, 1-(or 2- or 3-)ethyl-1-(or 2-)propenyl, 1-(or 2- or 3- or 4-)-
30 methyl-1-(or 2- or 3-)butenyl, and the like, in which more preferable example may be C₂-C₄ alkenyl.

Suitable "protected amino" and "protected amino moiety" in the term "acyl having protected amino" may include an acylamino or an amino group substituted by a
35 conventional protecting group such as ar(lower)alkyl which

may have suitable substituent(s) (e.g., benzyl, trityl, etc.) or the like.

Suitable "acyl" and "acyl moiety" in the term "acylamino", "acyl having protected hydroxy", "acyl having hydroxy", "acyl having protected amino", "acyl having amino", "acyl having a leaving group" and "acyl having N-containing heterocyclic group" may include carbamoyl, cyclo(lower)alkylcarbamoyl, aliphatic acyl group and acyl group containing an aromatic ring, which is referred to as aromatic acyl, or heterocyclic ring, which is referred to as heterocyclic acyl.

Suitable example of said acyl may be illustrated as follows :

- Carbamoyl; Thiocarbamoyl;
- 15 cyclo(lower)alkylcarbonyl (e.g., cyclopropylcarbonyl, cyclohexylcarbonyl, etc.);
- Aliphatic acyl such as lower or higher alkanoyl (e.g., formyl, acetyl, propanoyl, isobutyryl, butanoyl, pivaloyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl,
- 20 3,3-dimethylbutanoyl, 2,2-dimethylbutanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl, icosanoyl, etc.);
- 25 lower or higher alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, isobutyloxycarbonyl, t-butoxycarbonyl, t-pentyloxycarbonyl, heptyloxycarbonyl, etc.);
- lower alkoxyglyoxyloyl (e.g., methoxalyl, ethoxalyl, etc.),
- 30 lower or higher alkylsulfonyl (e.g., methylsulfonyl, ethylsulfonyl, etc.);
- lower or higher alkoxysulfonyl (e.g., methoxysulfonyl, ethoxysulfonyl, etc.); or the like;
- Aromatic acyl such as
- 35 aroyl (e.g., benzoyl, toluoyl, naphthoyl, etc.);

- ar(lower)alkanoyl [e.g., phenyl(lower)alkanoyl (e.g., phenylacetyl, phenylpropanoyl, phenylbutanoyl, phenylisobutanoyl, phenylpentanoyl, phenylhexanoyl, etc.), naphthyl(lower)alkanoyl (e.g., naphthylacetyl, naphthylpropanoyl, naphthylbutanoyl, etc.), etc.];
- 5 ar(lower)alkenoyl [e.g., phenyl(lower)alkenoyl (e.g., phenylpropenoyl, phenylbutenoyl, phenylmethacryloyl, phenylpentenoyl, phenylhexenoyl, etc.), naphthyl(lower)alkenoyl (e.g., naphthylpropenoyl, naphthylbutenoyl, etc.), etc.];
- 10 ar(lower)alkoxycarbonyl [e.g. phenyl(lower)alkoxycarbonyl (e.g., benzyloxycarbonyl, etc.), etc.]; aryloxycarbonyl (e.g., phenoxycarbonyl, naphthyloxycarbonyl, etc.);
- 15 arylthio(lower)alkanoyl [e.g., phenylthio(lower)alkanoyl (e.g., phenylthioacetyl, phenylthiopropenoyl, etc.), etc.]; aryloxy(lower)alkanoyl (e.g., phenoxyacetyl, phenoxypropionyl, etc.);
- 20 arylcarbamoyl (e.g., phenylcarbamoyl, etc.); aryl-thiocarbamoyl (e.g., phenyl-thiocarbamoyl, etc.); arylglyoxyloyl (e.g., phenylglyoxyloyl, naphthylglyoxyloyl, etc.);
- 25 arylsulfonyl (e.g., phenylsulfonyl, p-tolylsulfonyl, etc.); or the like;

- Heterocyclic acyl such as heterocycliccarbonyl; heterocycliccarbamoyl; heterocyclic(lower)alkanoyl (e.g., heterocyclicacetyl, heterocyclicpropanoyl, heterocyclicbutanoyl, heterocyclicpentanoyl, heterocyclichexanoyl, etc.);
- 30 heterocyclic(lower)alkenoyl (e.g., heterocyclicpropenoyl, heterocyclicbutenoyl, heterocyclicpentenoyl, heterocyclichexenoyl, etc.); heterocyclicglyoxyloyl; or the like;
- 35 in which suitable "heterocyclic moiety" in the terms

"heterocycliccarbonyl", "heterocycliccarbamoyl",
"heterocyclic(lower)alkyl", heterocyclic(lower)alkenoyl"
and "heterocyclicglyoxyloyl" as mentioned above means, in
more detail, saturated or unsaturated, monocyclic or
5 polycyclic heterocyclic group containing at least one
hetero-atom such as an oxygen, sulfur, nitrogen atom and
the like.

And, especially preferable heterocyclic group may be
heterocyclic group such as

10 unsaturated 3 to 8-membered (more preferably 5 or 6-
membered) heteromonocyclic group containing 1 to 4
nitrogen atom(s), for example, pyrrolyl, pyrrolinyl,
imidazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidyl,
pyrazinyl, pyridazinyl, triazolyl (e.g.,
15 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl,
2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g.,
1H-tetrazolyl, 2H-tetrazolyl, etc.), etc.;

saturated 3 to 8-membered (more preferably 5 or
6-membered) heteromonocyclic group containing 1 to 4
20 nitrogen atom(s), for example, pyrrolidinyl,
imidazolidinyl, piperidyl, piperazinyl, etc.;

unsaturated condensed heterocyclic group containing 1
to 4 nitrogen atom(s), for example, indolyl, isoindolyl,
indolinyl, indolizinyll, benzimidazolyl, quinolyl,
25 isoquinolyl, indazolyl, benzotriazolyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-
membered) heteromonocyclic group containing 1 to 2 oxygen
atom(s) and 1 to 3 nitrogen atom(s), for example,
oxazolyl, isoxazolyl, oxadiazolyl (e.g.,
30 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl,
etc.), etc.;

saturated 3 to 8-membered (more preferably 5 or 6-
membered) heteromonocyclic group containing 1 to 2 oxygen
atom(s) and 1 to 3 nitrogen atom(s), for example,
35 morpholinyl, sydnonyl, etc.;

unsaturated condensed heterocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, benzoxazolyl, benzoxadiazolyl, etc.;

5 unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolyl, isothiazolyl, thiadiazolyl (e.g., 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.),
10 dihydrothiazinyl, etc.;

saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolidinyl, etc.;

15 unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 sulfur atom(s), for example, thienyl, dihydrodithiynyl, dihydrodithionyl, etc.;

20 saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 oxygen atom(s), for example, tetrahydrofuryl, tetrahydropyranyl, etc.;

25 unsaturated condensed heterocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, benzothiazolyl, benzothiadiazolyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen atom, for example, furyl, etc.;

30 spiro heterocyclic group containing 1 to 2 oxygen atom(s), for example, dioxaspirooundecanyl (e.g., 1,5-dioxaspiro[5,5]undecanyl, etc.), etc.;

35 unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen atom and 1 to 2 sulfur atom(s), for example, dihydrooxathiinyl, etc.;

unsaturated condensed heterocyclic group containing 1 to 2 sulfur atom(s), for example, benzothienyl, benzodithiyl, etc.;

5 unsaturated condensed heterocyclic group containing an oxygen atom and 1 to 2 sulfur atom(s), for example benzoxathiyl, etc.; and the like.

The acyl moiety as stated above may have one to ten, same or different, suitable substituent(s) such as lower alkyl (e.g., methyl, ethyl, propyl, etc.); lower alkoxy (e.g., methoxy, ethoxy, propoxy, etc.); lower alkylthio (e.g., methylthio, ethylthio, etc.); lower alkylamino (e.g., methylamino, ethylamino, propylamino, etc.); 10 mono(or di or tri)halo(lower)alkyl (e.g., fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, bromomethyl, 15 dibromomethyl, tribromomethyl, 1 or 2-fluoroethyl, 1 or 2-bromoethyl, 1 or 2-chloroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, etc.), di(lower)alkylamino (e.g. dimethylamino, diethylamino, etc.); cyclo(lower)alkyl (e.g., cyclopropyl, cyclopentyl, cyclohexyl, etc.); 20 cyclo(lower)alkenyl (e.g., cyclohexenyl, cyclohexadienyl, etc.); halogen (e.g., fluorine, chlorine, bromine, iodine); amino, protected amino as mentioned above; hydroxy; protected hydroxy as mentioned below; cyano; 25 nitro; carboxy; protected carboxy as mentioned below; sulfo; aryl (e.g., phenyl, naphthyl, etc.); sulfamoyl; imino; oxo; amino(lower)alkyl (e.g., aminomethyl, aminoethyl, etc.); carbamoyloxy; hydroxy(lower)alkyl (e.g., hydroxymethyl, 1 or 2-hydroxyethyl, 1 or 2 or 30 3-hydroxypropyl, etc.) or the like.

Suitable "hydroxy protective group" in the term "protected hydroxy" and "acyl having protected hydroxy" may include acyl as mentioned above, phenyl(lower)alkyl which may have one or more suitable substituent(s) (e.g., 35 benzyl, 4-methoxybenzyl, trityl, etc.), trisubstituted

silyl [e.g., tri(lower)alkylsilyl (e.g. trimethylsilyl, t-butyldimethylsilyl, etc.), etc.], tetrahydropyranyl and the like.

5 Suitable "aryl" and "aryl moiety" in the terms "ar(lower)alkyl", "ar(lower)alkenyl" and "ar(C₁-C₅)alkyl" may include phenyl, naphthyl and the like.

 Suitable "leaving group" and "leaving group moiety" in the term "acyl having a leaving group" may include acid residue and the like.

10 Suitable "acid residue" may include halogen (e.g., fluorine, chlorine, bromine, iodine), acyloxy [e.g., sulfonyloxy (e.g., phenylsulfonyloxy, tosyloxy, mesyloxy, etc.), lower alkanoyloxy (e.g., acetyloxy, propionyloxy, etc.), etc.] and the like.

15 Suitable "halogen" may include fluorine, bromine, chlorine, iodine.

 Suitable "protected carboxy" and "protected carboxy moiety" in the term "protected carboxy(lower)alkyl" may include esterified carboxy and the like. And suitable
20 example of said ester may be the ones such as lower alkyl ester (e.g., methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, t-butyl ester, pentyl ester, t-pentyl ester, hexyl ester, etc.);
25 lower alkenyl ester (e.g., vinyl ester, allyl ester, etc.); lower alkynyl ester (e.g., ethynyl ester, propynyl ester, etc.); lower alkoxy(lower)alkyl ester (e.g., methoxymethyl ester, ethoxymethyl ester, isopropoxy ester, 1-methoxyethyl ester, 1-ethoxyethyl ester, etc.); lower
30 alkylthio(lower)alkyl ester (e.g., methylthiomethyl ester, ethylthiomethyl ester, ethylthioethyl ester, isopropoxythiomethyl ester, etc.); mono(or di or tri)halo-(lower)alkyl ester (e.g., 2-iodoethyl ester, 2,2,2-trichloroethyl ester, etc.); lower
35 alkanoyloxy(lower)alkyl ester (e.g., acetoxymethyl ester, propionyloxymethyl ester, butyryloxymethyl ester,

valeryloxymethyl ester, pivaloyloxymethyl ester, hexanoyloxymethyl ester, 1-acetoxyethyl ester, 2-acetoxyethyl ester, 2-propionyloxyethyl ester, etc.); cyclo(lower)alkyl ester (e.g., cyclopropyl ester, cyclopentyl ester, cyclohexyl ester, etc.); lower alkoxy-carbonyloxy(lower)alkyl ester (e.g., methoxycarbonyloxymethyl ester, ethoxycarbonyloxymethyl ester, propoxycarbonyloxymethyl ester, 1-(or 2-)[methoxy-carbonyloxy]ethyl ester, 1-(or 2-)[ethoxycarbonyloxy]ethyl ester, 1-(or 2-)[propoxycarbonyloxy]ethyl ester, 1-(or 2-)[isopropoxycarbonyloxy]ethyl ester, etc.); lower alkanesulfonyl(lower)alkyl ester (e.g., mesylmethyl ester, 2-mesyloxyethyl ester, etc.); lower alkoxy-carbonyloxy-(lower)alkyl ester (e.g., methoxycarbonyloxymethyl ester, ethoxycarbonyloxymethyl ester, propoxycarbonyloxymethyl ester, t-butoxycarbonyloxymethyl ester, 1-(or 2-)[methoxycarbonyloxy]ethyl ester, 1-(or 2-)[ethoxycarbonyloxy]ethyl ester, 1-(or 2-)[isopropoxycarbonyloxy]ethyl ester, etc.); phthalidylidene(lower)alkyl ester, or (5-lower alkyl-2-oxo-1,3-dioxol-4-yl)(lower)alkyl ester [e.g., (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, (5-ethyl-2-oxo-1,3-dioxol-4-yl)methyl ester, (5-propyl-2-oxo-1,3-dioxol-4-yl)ethyl ester, etc.]; ar(lower)alkyl ester, for example, phenyl(lower)alkyl ester which may have one or more suitable substituent(s) (e.g., benzyl ester, 4-methoxybenzyl ester, 4-nitrobenzyl ester, phenethyl ester, trityl ester, benzhydryl ester, bis(methoxyphenyl)methyl ester, 3,4-dimethoxybenzyl ester, 4-hydroxy-3,5-di-t-butylbenzyl ester, etc.); aryl ester which may have one or more suitable substituent(s) such as substituted or unsubstituted phenyl ester (e.g., phenyl ester, tolyl ester, t-butylphenyl ester, xylyl ester, mesityl ester, cumenyl ester, 4-chlorophenyl ester, 4-methoxyphenyl ester, etc.);

tri(lower)alkyl silyl ester; lower alkylthioester (e.g., methylthioester, ethylthioester, etc.) and the like.

Suitable "lower alkylene" may include straight or branched one such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, methylmethylene, ethylethylene, propylene, and the like, in which more preferable example may be C_1 - C_4 alkylene.

Suitable "heterocyclic group" can be referred to the ones as exemplified above.

Suitable "bridged tricyclicalkyl" may include tricyclobutyl, tricyclopentyl, tricyclohexyl, tricycloheptyl, tricyclooctyl, tricyclononanyl, tricyclodecanoyl (e.g., adamantanyl, etc.), tricycloundecanyl, and the like.

Suitable "cyclo(lower)alkyl" and "cyclo(lower)alkyl moiety" in the terms "cyclo(lower)alkyl-(lower)alkyl" and "cyclo(lower)alkyl-(C_1 - C_5)alkyl" may include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

Suitable " C_1 - C_5 alkyl" and " C_1 - C_5 alkyl moiety" in the terms "cyclo(lower)alkyl-(C_1 - C_5)alkyl" and " $ar(C_1$ - C_5)alkyl" may include straight or branched one having 1 to 5 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, tert-pentyl, neopentyl, and the like.

Suitable "N-containing heterocyclic group" and "N-containing heterocyclic group moiety" in the term "acyl having N-containing heterocyclic group" may include

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, dihydropyridyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.) tetrazolyl (e.g., 1H-tetrazolyl, 2H-tetrazolyl, etc.), etc.;

saturated 3 to 8-membered (more preferably 5 or

6-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl, etc.;

5 unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), for example, indolyl, isoindolyl, indolinyl, etc.;

10 saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, morpholinyl, etc.;

15 saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolidinyl, etc.; and the like.

20 Suitable substituent" in the term" heterocyclic group which may have suitable substituent(s)" may include lower alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, neopentyl, t-pentyl, hexyl, etc.), lower alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, t-butoxy, pentyloxy, neopentyloxy, t-pentyloxy, hexyloxy, etc.), lower alkenyl (e.g., vinyl, 1-propenyl, allyl, 1-methylallyl, 1 or 2 or 3-butenyl, 1 or 2 or 3 or 4-pentenyl, 1 or 2 or 3 or 4 or 5-hexenyl, etc.), lower alkynyl (e.g., ethynyl, 1-propynyl, propargyl, 1-methylpropargyl, 1-methylpropargyl, 1 or 2 or 3-butynyl, 1 or 2 or 3 or 4-pentynyl, 1 or 2 or 3 or 4 or 5-hexynyl, etc.), mono(or di or tri)halo(lower)alkyl (e.g., fluoromethyl, difluoromethyl, trifluoromethyl, 25 chloromethyl, dichloromethyl, trichloromethyl, bromomethyl, dibromomethyl, tribromomethyl, 1 or 2-fluoroethyl, 1 or 2-bromoethyl, 1 or 2-chloroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, etc.), halogen (e.g., chlorine, bromine, fluorine, iodine), carboxy, 30 protected carboxy, hydroxy, protected hydroxy, aryl (e.g.,

phenyl, naphthyl, etc.), ar(lower)alkyl such as phenyl(lower)alkyl (e.g., benzyl, phenethyl, phenylpropyl, etc.), carboxy(lower)alkyl, protected carboxy(lower)alkyl, nitro, amino, protected amino, di(lower)alkylamino (e.g.,
5 dimethylamino, diethylamino, diisopropylamino, ethylmethylamino, isopropylmethylamino, ethylmethylamino, ethylpropylamino, etc.), hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, acyl as mentioned above, cyano, mercapto, lower alkylthio (e.g., methylthio, ethylthio,
10 propylthio, isopropylthio, butylthio, etc.), imino, and the like.

Suitable "substituent" in the term "aryl which may have suitable substituent", "ar(lower)alkyl which may have
15 suitable substituent(s)" and "ar(C₁-C₅)alkyl which may have suitable substituent(s)" may include lower alkyl (e.g., methyl, ethyl propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, neopentyl, t-pentyl, hexyl, etc.), lower alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy,
20 isobutoxy, t-butoxy, pentyloxy, neopentyloxy, t-pentyloxy, hexyloxy, etc.), lower alkenyl (e.g., vinyl, 1-propenyl, allyl, 1-methylallyl, 1 or 2 or 3-butenyl, 1 or 2 or 3 or 4-pentenyl, 1 or 2 or 3 or 4 or 5-hexenyl, etc.), lower alkynyl (e.g., ethynyl, 1-propynyl, propargyl,
25 1-methylpropargyl, 1-methylpropargyl, 1 or 2 or 3-butynyl, 1 or 2 or 3 or 4-pentynyl, 1 or 2 or 3 or 4 or 5-hexynyl, etc.), mono(or di or tri)halo(lower)alkyl (e.g., fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl,
30 bromomethyl, dibromomethyl, tribromomethyl, 1 or 2-fluoroethyl, 1 or 2-bromoethyl, 1 or 2-chloroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, etc.), halogen (e.g., chlorine, bromine, fluorine, iodine), carboxy, protected carboxy, hydroxy, protected hydroxy, aryl (e.g.,
35 phenyl, naphthyl, etc.), ar(lower)alkyl such as

phenyl(lower)alkyl (e.g., benzyl, phenethyl, phenylpropyl, etc.), carboxy(lower)alkyl, protected carboxy(lower)alkyl, nitro, amino, protected amino, di(lower)alkylamino (e.g., dimethylamino, diethylamino, diisopropylamino, ethylmethylamino, isopropylmethylamino, ethylmethylamino, ethylpropylamino, etc.), hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, acyl as mentioned above, cyano, mercapto, lower alkylthio (e.g., methylthio, ethylthio, propylthio, isopropylthio, butylthio, etc.), imino, and the like.

The processes for preparing the object and starting compounds are explained in detail in the following.

Process (1)

The compound (Ia) or a salt thereof can be prepared by subjecting the compound (II) or a salt thereof to reduction reaction.

Reduction is carried out in a conventional manner, including chemical reduction and catalytic reduction.

Suitable reducing reagent to be used in chemical reduction are hydrides (e.g., hydrogen iodide, hydrogen sulfide, lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride, etc.); a combination of borane, and tetrahydrofuran or di(lower)alkyl sulfide (e.g., dimethyl sulfide, etc.); or a combination of a metal (e.g., tin, zinc, iron, etc.) or metallic compound (e.g., chromium chloride, chromium acetate, etc.) and an organic acid or an inorganic acid (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.).

Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts (e.g., platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.), palladium

catalysts (e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.), nickel catalysts (e.g., reduced nickel, nickel oxide, Raney nickel, etc.), cobalt catalysts (e.g., reduced cobalt, Raney cobalt, etc.), iron catalysts (e.g., reduced iron, Raney copper, Ullman copper, etc.), and the like.

The reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, alcohol (e.g., methanol, ethanol, propanol, etc.), tetrahydrofuran, dioxane, N,N-dimethylformamide, or a mixture thereof.

Additionally, in case that the above-mentioned acids to be used in chemical reduction are in liquid, they can also be used as a solvent.

The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.

Process (2)

The compound (Ic) or a salt thereof can be prepared by subjecting the compound (Ib) or its reactive derivative at the imino group or a salt thereof to acylation reaction.

Suitable acylating agent to be used in the present acylation reaction may include the compound of the formula :



(wherein R_a^4 is acyl)
or its reactive derivative or a salt thereof.

Suitable reactive derivative at the imino group of the compound (Ib) may include a silyl derivative formed by the reaction of the compound (Ib) with a silyl compound such as N,O-bis(trimethylsilyl)acetamide, N-trimethyl-

silylacetamide or the like; a derivative formed by the reaction of the compound (Ib) with phosphorus trichloride or phosgene, and the like.

Suitable reactive derivative of the compound (XIX)
5 may include an acid halide, an acid anhydride, an activated ester, isothiocyanate, isocyanate, and the like. The suitable example may be an acid chloride; acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid (e.g., dialkylphosphoric acid,
10 phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.), dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, alkanesulfuric acid (e.g., methanesulfonic acid, ethanesulfonic acid, etc.), sulfuric
15 acid, alkylcarbonic acid, aliphatic carboxylic acid (e.g., pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.); aromatic carboxylic acid (e.g., benzoic acid, etc.); a symmetrical acid anhydride; an activated amide with
20 imidazole, 4-substituted imidazole, dimethylpyrazole, triazole or tetrazole; an activated ester (e.g., cyanomethyl ester, methoxymethyl ester, dimethyliminomethyl [$(\text{CH}_3)_2\text{N}^+=\text{CH}-$] ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl
25 ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenylthio ester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.); an ester
30 with a N-hydroxy compound (e.g., N,N-dimethylhydroxyamine, 1-hydroxy-2-(1H)-pyridone, N-hydroxysuccinimide, N-hydroxybenzotriazole, N-hydroxyphthalimide, 1-hydroxy-6-chloro-1H-benzotriazole, etc.); substituted or unsubstituted aryl isocyanate; substituted or unsubstituted
35 aryl isothiocyanate, and the like. These reactive

derivatives can optionally be selected from them according to the kind of the compound (XIX) to be used.

The reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvents which do not adversely influence the reaction. These conventional solvents may also be used in a mixture with water.

When the compound (XIX) is used in free acid form or its salt form in the reaction, the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide; N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide; N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide; N,N-carbonyl-bis(2-methylimidazole); pentamethyleneketene-N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1-alkoxy-1-chloroethylene; trialkyl phosphite; isopropyl polyphosphate; phosphorous oxychloride (phosphoryl chloride); phosphorous trichloride; thionyl chloride; oxalyl chloride; triphenylphosphite; 2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5-(m-sulfophenyl)isoxazolium hydroxide intra-molecular salt; 1-(p-chlorobenzenesulfonyloxy)-6-chloro-1H-benzotriazole; so-called Vilsmeier reagent prepared by the reaction of N,N-dimethylformamide with thionyl chloride, phosgene, phosphorous oxychloride, etc.; or the like.

The reaction may be carried out in the presence of an inorganic or an organic base such as an alkali metal (e.g., sodium, potassium, etc.), an alkali metal hydroxide (e.g., sodium hydroxide, potassium hydroxide, etc.), an

alkali metal hydrogencarbonate (e.g., sodium hydrogencarbonate, potassium hydrogencarbonate, etc.), alkali metal carbonate (e.g., sodium carbonate, potassium carbonate, etc.), tri(lower)alkylamine (e.g.,
5 trimethylamine, triethylamine, diisopropylethylamine, etc.), alkali metal hydride (e.g., sodium hydride, etc.), alkali metal (lower)alkoxide (e.g., sodium methoxide, sodium ethoxide, etc.), pyridine, lutidine, picoline, dimethylaminopyridine, N-(lower)alkylmorpholine,
10 N,N-di(lower)alkylbenzylamine, N,N-di(lower)alkylamine, N-(lower)alkylpyrrolidone (e.g., N-methyl-2-pyrrolidone, etc.), or the like.

The reaction may be carried out in the presence of an acid including Lewis acid.

15 Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.] and an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g.
20 zinc chloride, zinc bromide, etc.), etc.] and the like.

When the acid, the base and/or the starting compound are in liquid, they can be used also as a solvent.

The reaction temperature is not critical and the reaction is usually carried out under cooling to heating.

25 The present invention includes, within the scope of the invention, the case that hydrogen in R^3 is transformed into acyl group during the reaction.

Process (3)

30 The compound (Ie) or a salt thereof can be prepared by subjecting the compound (Id) or a salt thereof to reduction reaction.

This reduction can be carried out in a similar manner to that of the aforementioned Process (1), and therefore
35 the reagents to be used and the reaction conditions (e.g.,

solvent, reaction temperature, etc.) can be referred to those of the Process (1).

Process (4)

5 The compound (If) or a salt thereof can be prepared by subjecting the compound (III) or a salt thereof to reduction reaction.

10 This reduction can be carried out in a similar manner to that of the aforementioned Process (1), and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (1).

Process (5)

15 The compound (Ih) or a salt thereof can be prepared by subjecting the compound (Ig) or a salt thereof to elimination reaction of the hydroxy protective group.

20 Suitable method of this elimination reaction may include conventional one such as hydrolysis, reduction and the like.

(i) For Hydrolysis :

The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.

25 Suitable base may include an inorganic base and an organic base such as an alkali metal [e.g., sodium, potassium, etc.], an alkaline earth metal [e.g., magnesium, calcium, etc.], the hydroxide or carbonate or hydrogencarbonate thereof, trialkylamine [e.g., trimethylamine, triethylamine, etc.], picoline, 30 1,5-diazabicyclo[4.3.0]-non-5-ene, or the like.

35 Suitable acid may include an organic acid [e.g., formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], and an inorganic acid [e.g., hydrochloric acid, hydrobromic acid, sulfuric acid,

hydrogen chloride, hydrogen bromide, etc.].

The elimination using Lewis acid such as trihaloacetic acid [e.g., trichloroacetic acid, trifluoroacetic acid, etc.], or the like is preferably
5 carried out in the presence of cation trapping agents [e.g., anisole, phenol, etc.].

The reaction is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane,
10 dichloromethane, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide, or any other organic solvent which does not adversely affect the reaction.

Among these solvents, hydrophilic solvents may be
15 used in a mixture with water.

The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.

(ii) For reduction :

20 Reduction is carried out in a conventional manner, including chemical reduction and catalytic reduction.

Suitable reducing reagent to be used in chemical reduction are hydrides (e.g., hydrogen iodide, hydrogen sulfide, lithium aluminum hydride, sodium borohydride,
25 sodium cyanoborohydride, etc.), or a combination of a metal (e.g., tin, zinc, iron, etc.) or metallic compound (e.g., chromium chloride, chromium acetate, etc.) and an organic acid or an inorganic acid (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid,
30 p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.).

Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts (e.g., platinum plate, spongy platinum, platinum black, colloidal
35 platinum, platinum oxide, platinum wire, etc.), palladium

catalysts (e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.), nickel catalysts (e.g.,
5 reduced nickel, nickel oxide, Raney nickel, etc.), cobalt catalysts (e.g., reduced cobalt, Raney cobalt, etc.), iron catalysts (e.g., reduced iron, etc.), and the like.

The reduction is usually carried out in a
10 conventional solvent which does not adversely influence the reaction such as water, alcohol (e.g., methanol, ethanol, propanol, etc.), N,N-dimethylformamide, tetrahydrofuran, methylene dichloride, chloroform, dioxane, or a mixture thereof.

15 Additionally, in case that the above-mentioned acids to be used in chemical reduction are in liquid, they can also be used as a solvent.

The reaction temperature of this reduction is not critical and the reaction is usually carried out under
20 cooling to warming.

Process (6)

The compound (Ij) or a salt thereof can be prepared
25 by subjecting the compound (Ii) or a salt thereof to elimination reaction of the amino protective group.

This reaction can be carried out in a similar manner to that of the aforementioned Process (5), and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to
30 those of the Process (5).

Process (7)

The compound (Il) or a salt thereof can be prepared
35 by reacting the compound (Ik) or a salt thereof with the compound (IV) or a salt thereof.

This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction. These conventional solvent may also be used in a mixture with water.

The reaction temperature is not critical and the reaction is usually carried out under cooling to heating.

The reaction is usually carried out in the presence of an inorganic or an organic base such as an alkali metal (e.g., sodium, potassium, etc.), an alkali metal hydroxide (e.g., sodium hydroxide, potassium hydroxide, etc.), an alkali metal hydrogencarbonate (e.g., sodium hydrogencarbonate, potassium hydrogencarbonate, etc.), alkali metal carbonate (e.g., sodium carbonate, potassium carbonate, etc.), tri(lower)alkylamine (e.g., trimethylamine, triethylamine, diisopropylethylamine, etc.), alkali metal hydride (e.g., sodium hydride, etc.), alkali metal (lower)alkoxide (e.g. sodium methoxide, sodium ethoxide, etc.), pyridine, lutidine, picoline, dimethylaminopyridine, N-(lower)alkylmorpholine, N,N-di(lower)alkylbenzylamine, N,N-di(lower)alkylaniline or the like.

When the base and/or the starting compound are in liquid, they can be used also as a solvent.

Process (A)

The compound (VII) or a salt thereof can be prepared by reacting the compound (V) or a salt thereof with the compound (VI) or a salt thereof.

This reaction can be carried out in the manner disclosed in Preparation 2 or similar manners thereto.

Process (B)

The compound (IX) or a salt thereof can be prepared by reacting the compound (VII) or a salt thereof with the compound (VIII) or a salt thereof.

5 This reaction can be carried out in the manner disclosed in Preparation 3 or similar manners thereto.

Process (C)

10 The compound (X) or a salt thereof can be prepared by subjecting the compound (IX) or a salt thereof to cleavage reaction of O-N bond.

This reaction can be carried out in the manner disclosed in Preparation 4 or similar manners thereto.

15 Process (D) - (1)

The compound (XI) or a salt thereof can be prepared by subjecting the compound (X) or a salt thereof to halogenation reaction.

20 This halogenation is usually carried out by using a conventional halogenating agent such as halogen (e.g., chlorine, bromine, etc.), phosphorus trihalide (e.g., phosphorus tribromide, phosphorus trichloride, etc.), phosphorus pentahalide, (e.g., phosphorus pentachloride, phosphorus pentabromide, etc.), phosphorus oxychloride
25 (e.g., phosphoryl trichloride, phosphoryl monochloride, etc.), thionyl halide (e.g., thionyl chloride, thionyl bromide, etc.), oxalyl halide (e.g., oxalyl chloride, oxalyl bromide, etc.) and the like.

30 This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), benzene, dioxane, N,N-dimethylformamide, tetrahydrofuran, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.

35 The reaction temperature is not critical and the

reaction is usually carried out under cooling to warming.

Process (D) - (2)

5 The compound (XIII) or a salt thereof can be prepared by reacting the compound (XI) or a salt thereof with the compound (XII) or a salt thereof.

10 This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.

15 The reaction temperature is not critical and the reaction is usually carried out under warming to heating.

Process (E)

The compound (X) or a salt thereof can be prepared by reacting the compound (XIV) or a salt thereof with the compound (XV) or a salt thereof.

20 This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction. These conventional solvent may also be used in a mixture with water.

25 The reaction temperature is not critical and the reaction is usually carried out under warming to heating.

30 The reaction is usually carried out in the presence of an inorganic or an organic base such as an alkali metal (e.g., sodium, potassium, etc.), an alkali metal hydroxide (e.g., sodium hydroxide, potassium hydroxide, etc.), an alkali metal hydrogencarbonate (e.g., sodium hydrogencarbonate, potassium hydrogencarbonate, etc.),
35 alkali metal carbonate (e.g., sodium carbonate, potassium

carbonate, etc.), tri(lower)alkylamine (e.g., trimethylamine, triethylamine, diisopropylethylamine, etc.), alkali metal hydride (e.g., sodium hydride, etc.), alkali metal (lower)alkoxide (e.g., sodium methoxide, sodium ethoxide, etc.), pyridine, lutidine, picoline, dimethylaminopyridine, N-(lower)alkylmorpholine, N,N-di(lower)alkylbenzylamine, N,N-di(lower)alkylaniline or the like.

When the base and/or the starting compound are in liquid, they can be also as a solvent.

Process (F)

The compound (XIII) or a salt thereof can be prepared by reacting the compound (X) or a salt thereof with the compound (XII) or a salt thereof.

This reaction is usually carried out in a solvent such as benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction.

The reaction temperature is not critical and the reaction is usually carried out under warming to heating.

The reaction is usually carried out in the presence of an acid including Lewis acid.

Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zinc bromide, etc.), etc.] and the like.

When the acid and/or the starting compound are in liquid, they can be also as a solvent.

Process (G)

The compound (XVI) or a salt thereof can be prepared

by subjecting the compound (XIII) or a salt thereof to diazotization reaction.

The reaction is usually carried out by using a conventional diazotizing agent such as a combination of an alkali metal nitrite (e.g., sodium nitrite, etc.) and an inorganic acid (e.g., hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, etc.), a combination of isopentyl nitrite and an organic acid (e.g., acetic acid, benzoic acid, etc.) and the like.

This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.

The reaction temperature is not critical and the reaction is usually carried out under cooling.

Process (H)

The compound (IIa) or a salt thereof can be prepared by reacting the compound (XVI) or a salt thereof with the compound (XVII) or a salt thereof.

This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylenechloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.

The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.

Process (I)

The compound (III) or a salt thereof can be prepared by reacting the compound (Ib) or a salt thereof with the compound (XVIII) or a salt thereof.

This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction. These conventional solvent may also be used in a mixture with water.

The reaction temperature is not critical and the reaction is usually carried out under cooling to heating.

The reaction is usually carried out in the presence of an acid including Lewis acid.

Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.] and an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zinc bromide, etc.), etc.] and the like.

When the acid and/or the starting compound are in liquid, they can be used also as a solvent.

Suitable "anion" may include anion derived from the materials used in this reaction such as acid residue [e.g., halogen (e.g., fluorine, chlorine, bromine, iodine), etc.], OH^- and the like.

Suitable salts of the object and starting compounds in Process (1)-(7) and (A)-(I) can be referred to the ones as exemplified for the compound (I).

The new pyrazole derivatives (I) and a pharmaceutically acceptable salt thereof of the present invention possess a strong inhibitory activity on the production of Interleukin-1 (IL-1) and a strong inhibitory activity on the production of tumor necrosis factor (TNF), and therefore are useful as an inhibitor on the production of Interleukin-1 (IL-1) and an inhibitor on the production of tumor necrosis factor (TNF).

Accordingly, the new pyrazole derivatives (I)

and a pharmaceutically acceptable salt thereof can be used for prophylactic and therapeutic treatment of IL-1 and TNF mediated diseases such as chronic inflammatory diseases (e.g. rheumatoid arthritis, osteoarthritis, etc.)

5 osteoporosis, rejection by transplantation, asthma, endotoxin shock, specific autoimmune diseases [e.g. ankylosing spondylitis, autoimmune hematological disorders (e.g. hemolytic anaemia, aplastic anaemia, pure red cell anaemia, idiopathic thrombocytopenia, etc.), systemic

10 lupus erythematosus, polychondritis, scleroderma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, idiopathic sprue, autoimmune

~~inflammatory bowel disease~~ (e.g. ulcerative colitis, Crohn's disease, etc.), endocrine opthalmopathy, Grave's

15 disease, sarcoidosis, multiple sclerosis, primary biliary cirrhosis, juvenile diabetes (diabetes mellitus type I), Reiter's syndrome, non infection uveitis, autoimmune keratitis (e.g. keratoconjunctivitis sicca, vernal keratoconjunctivitis, etc.), interstitial lung fibrosis,

20 psoriatic arthritis, glomerulonephritis {e.g. nephrotic syndrome (e.g. idiopathic nephrotic syndrome, minimal change nephropathy, etc.), etc.}, etc.}, cancer cachexia, AIDS cachexia, thrombosis, and the like.

In order to show the utilities of the pyrazole derivatives (I) and a pharmaceutically acceptable salt thereof of the present invention, pharmacological test data of the representative compounds of the pyrazole derivatives (I) are illustrated in the following.

25

30 The expression of each "Example 16-(5)" and Example 18-(2) in the following test means the compounds prepared in Example 16-(5) and Example 18-(2) respectively.

(a) Inhibitory activity on the production of Interleukin-1 (IL-1)

1. Test method

5

Purified human peripheral blood monocyte were stimulated with bacterial lipopolysaccharide ($1 \mu\text{g}/10^4$ cells) in the absence or presence of appropriately diluted test compound for 2 days at 37°C in a humidified 5% CO_2 atmosphere. Culture supernatants were tested for IL-1 ELISA assay.

10

Test compound was dissolved in absolute DMSO (dimethyl sulfoxide) to achieve 10 mM stock solutions and was subsequently diluted in serum free RPMI1640.

15

IL-1 levels were quantified by a commercial ELISA kit (Ohtsuka assay, Japan) using a sandwich technique. The sensitivity levels for the detection of IL-1 β were 20 pg/ml.

20

The inhibitory concentration that caused a 50% inhibition (IC_{50}) was calculated by regression analysis of the dose-response data.

2. Test result

25

Test compound	IC_{50} (M)
Example 16-(5)	9.2×10^{-8}
Example 18-(2)	8.8×10^{-8}

30

(b) Inhibitory activity on the production of tumor necrosis factor (TNF)

1. Test method

35

Purified human peripheral blood monocyte were

stimulated with bacterial lipopolysaccharide ($1 \mu\text{g}/10^4$ cells) in the absence or presence of appropriately diluted test compound for 2 days at 37°C in a humidified 5% CO_2 atmosphere. Culture supernatants were tested for TNF ELISA assay.

TNF levels were quantified by a commercial ELISA kit (Endogen, Inc. USA) using a sandwich technique. The sensitivity levels for the detection of TNF were 12 pg/ml .

The inhibitory concentration that caused a 50% inhibition (IC_{50}) was calculated by regression analysis of the dose-response data.

2. Test result

Test compound	IC_{50} (M)
Example 16-(5)	9.1×10^{-8}
Example 18-(2)	1.1×10^{-7}

For therapeutic administration, the object compounds (I) of the present invention and pharmaceutically acceptable salts thereof are used in a form of the conventional pharmaceutical preparation in admixture with a conventional pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient which is suitable for oral, parenteral or external administration. The pharmaceutical preparation may be compounded in a solid form such as granule, capsule, tablet, dragee or suppository, or in a liquid form such as solution, suspension or emulsion for injection, ingestion, eye drops, etc. If needed, there may be included in the above preparation auxiliary substance such as stabilizing agent, wetting or emulsifying agent, buffer or any other commonly used additives.

The effective ingredient may usually be administered

with a unit dose of 0.001 mg/kg to 500 mg/kg, preferably 0.01 mg/kg to 10 mg/kg, 1 to 4 times a day. However, the above dosage may be increased or decreased according to age, weight and conditions of the patient or the administering method.

Preferred embodiments of the object compound (I) are as follows.

10 R^1 is phenyl which may have 1 to 3 (more preferably one or two) suitable substituent(s) [more preferably phenyl which may have 1 to 3 (more preferably one or two; most preferably one) substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, lower
15 alkenyl, lower alkynyl, mono(or di or tri)halo(lower)alkyl, halogen, carboxy, protected carboxy, hydroxy, protected hydroxy, aryl, ar(lower)alkyl, carboxy(lower)alkyl, protected carboxy(lower)alkyl, amino, protected amino,
20 di(lower)alkylamino, hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, nitro, acyl, cyano, mercapto, lower alkylthio and imino; most preferably halophenyl]; or
pyridyl which may have 1 to 3 (more preferably one or
25 two) suitable substituent(s) [more preferably pyridyl which may have 1 to 3 (more preferably one or two; most preferably one) substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, lower alkenyl, lower alkynyl, mono(or di or
30 tri)halo(lower)alkyl, halogen, carboxy, protected carboxy, hydroxy, protected hydroxy, aryl, ar(lower)alkyl, carboxy(lower)alkyl, protected carboxy(lower)alkyl, amino, protected amino, di(lower)alkylamino, hydroxy(lower)alkyl, protected
35 hydroxy(lower)alkyl, nitro, acyl, cyano, mercapto,

lower alkylthio and imino;
most preferably pyridyl],

5 R^2 is phenyl which may have 1 to 3 (more preferably one or two) suitable substituent(s) [more preferably phenyl which may have 1 to 3 (more preferably one or two; most preferably one) substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, lower alkenyl, lower alkynyl, mono(or di or tri)halo(lower)alkyl, halogen, carboxy, protected
10 carboxy, hydroxy, protected hydroxy, aryl, ar(lower)alkyl, carboxy(lower)alkyl, protected carboxy(lower)alkyl, amino, protected amino, di(lower)alkylamino, hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, nitro, acyl, cyano, mercapto,
15 lower alkylthio and imino; most preferably halophenyl]; or pyridyl which may have 1 to 3 (more preferably one or two) suitable substituent(s) [more preferably pyridyl which may have 1 to 3 (more preferably one or two; most preferably one) substituent(s) selected from the
20 group consisting of lower alkyl, lower alkoxy, lower alkenyl, lower alkynyl, mono(or di or tri)halo(lower)alkyl, halogen, carboxy, protected carboxy, hydroxy, protected hydroxy, aryl,
25 ar(lower)alkyl, carboxy(lower)alkyl, protected carboxy(lower)alkyl, amino, protected amino, di(lower)alkylamino, hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, nitro, acyl, cyano, mercapto, lower alkylthio and imino;
30 most preferably pyridyl, halopyridyl or lower alkoxy pyridyl],

R^3 is hydrogen or lower alkanoyl,

R^4 is hydrogen;
lower alkyl;

35 cyclo(lower)alkyl;

cyclo(lower)alkyl-(lower)alkyl;
carboxy(lower)alkyl;
esterified carboxy(lower)alkyl [more preferably
lower alkoxycarbonyl(lower)alkyl];
5 phenyl(lower)alkyl which may have 1 to 3 (more
preferably one or two) suitable substituent(s) [more
preferably phenyl(lower)alkyl which may have 1 to 3
(more preferably one or two) substituent(s) selected
from the group consisting of halogen, lower alkyl,
10 lower alkoxy, lower alkenyl, lower alkynyl, mono(or
di or tri)halo(lower)alkyl and di(lower)alkylamino;
most preferably mono(or di)halophenyl(lower)alkyl];
adamantanyl; phenyl(lower)alkenyl; tetrahydropyranyl,
piperidyl or dioxaspioundecanyl, each of which may
15 have 1 to 3 (more preferably one or two)
substituent(s) selected from the group consisting of
lower alkyl and acyl [more preferably
tetrahydropyranyl, piperidyl or dioxaspioundecanyl,
each of which may have one or two substituent(s)
20 selected from the group consisting of lower alkyl and
lower alkanoyl;
most preferably tetrahydropyranyl,
lower alkylpiperidyl, lower alkanoylpiperidyl, or
di(lower)alkyldioxaspioundecanyl];
25 indanyl;
lower alkanoyl which may have 1 to 3 (more preferably
one or two) suitable substituent(s) [more preferably
lower alkanoyl which may have 1 to 3 (more preferably
one or two; most preferably one) substituent(s)
30 selected from the group consisting of carboxy,
protected carboxy, lower alkoxy, halogen, protected
amino, amino, hydroxy, protected hydroxy and
di(lower)alkylamino;
most preferably lower alkanoyl which may have a
35 substituent selected from the group consisting of

- carboxy, esterified carboxy, lower alkoxy, halogen,
lower alkoxycarbonylamino, lower alkanoylamino,
amino, hydroxy, acyloxy (more preferably lower
alkanoyloxy or cyclo(lower)alkylcarbonyloxy), and
5 di(lower)alkylamino];
lower alkoxycarbonyl;
lower alkoxyglyoxyloyl;
lower alkylsulfonyl;
cyclo(lower)alkylcarbonyl;
10 aroyl which may have 1 to 3 (more preferably one or
two) suitable substituent(s) [more preferably benzoyl
which may have 1 to 3 (more preferably one or two)
substituent(s) selected from the group consisting of
mono(or di or tri)halo(lower)alkyl, halogen, protected
15 hydroxy and hydroxy; most preferably benzoyl which may
have one or two substituent(s) selected from the group
consisting of trihalo(lower)alkyl, halogen, acyloxy
(more preferably lower alkanoyloxy) and hydroxy];
ar(lower)alkanoyl which may have 1 to 3 (more
20 preferably one or two) suitable substituent(s) [more
preferably phenyl(lower)alkanoyl which may have 1 to
3 (more preferably one or two) substituent(s)
selected from the group consisting of lower alkoxy,
aryl, halogen and mono(or di or tri)halo(lower)alkyl;
25 most preferably phenyl(lower)alkanoyl which may have
one or two substituent(s) selected from the group
consisting of lower alkoxy, phenyl, halogen and
trihalo(lower)alkyl];
ar(lower)alkenoyl [more preferably
30 phenyl(lower)alkenoyl];
arylthio(lower)alkanoyl [more preferably
phenylthio(lower)alkanoyl];
arylcarbamoyl [more preferably phenylcarbamoyl];
aryl-thiocarbamoyl [more preferably
35 phenyl-thiocarbamoyl];

arylglyoxyloyl which may have 1 to 3 (more preferably one or two) suitable substituent(s) [more preferably phenylglyoxyloyl which may have 1 to 3 (more preferably one or two; most preferably one) substituent(s) selected from the group consisting of mono(or di or tri)halo(lower)alkyl and lower alkoxy; most preferably phenylglyoxyloyl which may have a substituent selected from the group consisting of trihalo(lower)alkyl and lower alkoxy]; carbamoyl which may have one or two suitable substituent(s) selected from the group consisting of lower alkyl, hydroxy(lower)alkyl, protected hydroxy(lower)alkyl (more preferably acyloxy(lower)alkyl), lower alkoxy and cyclo(lower)alkyl; heterocycliccarbonyl [more preferably morpholinylcarbonyl]; heterocyclic(lower)alkanoyl [more preferably indolyl(lower)alkanoyl or morpholinyl(lower)alkanoyl]; or heterocycliccarbamoyl [more preferably piperidylcarbamoyl], and R^5 is hydrogen or lower alkyl.

The following Preparations and Examples are given for the purpose of illustrating the present invention in more detail.

30

35

Preparation 1

To a solution of 4-methylpyridine (74.4 g) and ethyl 4-fluorobenzoate (134.4 g) in dry tetrahydrofuran (600 ml) was added a 1.0M solution of lithium
5 bis(trimethylsilyl)amide in tetrahydrofuran (1.6 l) dropwise with ice cooling. The mixture was stirred at ambient temperature for 30 minutes. To the reaction mixture was added hexane (2.2 l) and the separated solid was collected, washed with hexane and dried. The obtained
10 solid was dissolved in 3N-hydrochloric acid (800 ml) and the solution was neutralized with an aqueous saturated sodium bicarbonate solution. The separated solid was collected, washed with water and dried to give
1-(4-fluorophenyl)-2-(pyridin-4-yl)ethan-1-one (148 g).
15 mp : 93-94°C
NMR (CDCl₃, δ) : 4.28 (2H, s), 7.09-7.25 (4H, m),
8.01 (1H, d, J=5Hz), 8.06 (1H, d, J=5Hz), 8.60
(2H, d, J=6Hz)

20 Preparation 2

A mixture of 1-(4-fluorophenyl)-2-(pyridin-4-yl)-ethan-1-one (5.12 g) and N,N-dimethylformamide dimethyl acetal (16 ml) was stirred at 100°C for 3 hours under
nitrogen. The cooled mixture was concentrated in vacuo.
25 The residue was crystallized from isopropyl ether to yield 3-dimethylamino-1-(4-fluorophenyl)-2-(pyridin-4-yl)-2-propen-1-one (6.15 g).
NMR (CDCl₃, δ) : 2.82 (6H, s), 6.99 (2H, t, J=9Hz),
7.03 (2H, d, J=6Hz), 7.35-7.55 (3H, m),
30 8.48 (2H, br)

Preparation 3

A mixture of 3-dimethylamino-1-(4-fluorophenyl)-2-(pyridin-4-yl)-2-propen-1-one (6.15 g) and hydroxylamine
35 hydrochloride (4.75 g) in dry ethanol (40 ml) was refluxed

for 20 minutes. The mixture was cooled and concentrated in vacuo. The residue was dissolved in dilute hydrochloric acid and then treated with an aqueous saturated sodium bicarbonate solution. The precipitates
5 were collected by filtration, washed with water, and dried to give 5-(4-fluorophenyl)-4-(pyridin-4-yl)isoxazole (5.35 g).

mp : 95-97°C

10 NMR (CDCl₃, δ) : 7.15 (2H, t, J=9Hz), 7.37 (2H, d, J=6Hz), 7.61 (2H, dd, J=5Hz and 9Hz), 8.46 (1H, s), 8.67 (2H, d, J=6Hz)

Preparation 4

15 A suspension of 5-(4-fluorophenyl)-4-(pyridin-4-yl)-isoxazole (5.35 g) in 1N sodium hydroxide aqueous solution (50 ml) was stirred for one hour at 60°C. The solution was cooled and adjusted to pH 6 with concentrated hydrochloric acid. The separated solid was collected,
20 washed with water, and dried to give 3-(4-fluorophenyl)-3-oxo-2-(pyridin-4-yl)propanenitrile (5.27 g).

mp : 222-225°C

25 NMR (CDCl₃ + CD₃OD, δ) : 7.11 (2H, t, J=9Hz), 7.77 (2H, dd, J=5Hz and 9Hz), 7.82 (2H, d, J=6Hz), 8.21 (2H, d, J=6Hz)

Preparation 5

30 A solution of 3-(4-fluorophenyl)-3-oxo-2-(pyridin-4-yl)propanenitrile (240 mg) in phosphoryl trichloride (3 ml) was stirred for 15 minutes at 100°C and then evaporated under reduced pressure. To the residue was added toluene and concentrated in vacuo, and the residue was dissolved in ethanol (2 ml). To the mixture was added hydrazine monohydrate (150 mg). The mixture was refluxed
35 for 3 hours, cooled, and poured into an aqueous saturated

sodium bicarbonate solution. The separated oil was extracted with a mixture of ethanol and dichloromethane (2:8). The extract was washed with water, dried and concentrated in vacuo. The residue was crystallized from methanol to yield 5-amino-3-(4-fluorophenyl)-4-(pyridin-4-yl)pyrazole (110 mg).

mp : >250°C

NMR (CDCl₃ + CD₃OD, δ) : 7.08 (2H, t, J=9Hz), 7.23 (2H, d, J=6Hz), 7.33 (2H, dd, J=5Hz and 9Hz), 8.42 (2H, d, J=6Hz)

Preparation 6

Sodium (2.48 g) was dissolved in dry ethanol (37 ml) under nitrogen atmosphere. To the solution was added 4-fluorophenylacetonitrile (11.65 g) and ethyl isonicotinate (16.41 ml) and the solution was refluxed for 3 hours. The reaction mixture was cooled and poured into water. The ethanol of the mixture was removed under reduced pressure. The resulting aqueous solution was washed with ether and neutralized with diluted hydrochloric acid. The separated solid was collected, washed with water and dried to give 2-(4-fluorophenyl)-3-oxo-3-(pyridin-4-yl)propanenitrile (16.43 g).

mp : 230-232°C

NMR (CDCl₃ + CD₃OD, δ) : 7.12 (2H, t, J=9Hz), 7.68 (2H, d, J=6Hz), 7.84 (2H, dd, J=5Hz and 9Hz), 8.69 (2H, d, J=6Hz)

Preparation 7

A mixture of 2-(4-fluorophenyl)-3-oxo-3-(pyridin-4-yl)propanenitrile (10 g), hydrazine monohydrate (2.4 ml) and acetic acid (5.2 ml) in dry benzene (100 ml) was refluxed for 4 hours. The reaction mixture was cooled and extracted with 3N-hydrochloric acid (80 ml x 3). The extracts were concentrated in vacuo to 100 ml of the

volume and the solution was neutralized with aqueous ammonia solution. The separated solid was collected, washed with water and dried to give 5-amino-4-(4-fluorophenyl)-3-(pyridin-4-yl)pyrazole (2.02 g).

5 mp : 116-118°C

NMR (CDCl₃ + CD₃OD, δ) : 7.12 (2H, t, J=9Hz),
7.25 (2H, dd, J=5Hz and 9Hz), 7.38 (2H, d,
J=6Hz), 8.46 (2H, d, J=6Hz)

10 Preparation 8

To a mixture of 5-amino-4-(4-fluorophenyl)-3-(pyridin-4-yl)pyrazole (100 mg) and concentrated hydrochloric acid (0.2 ml) in water (0.4 ml) was added sodium nitrite (28 mg) in water (0.12 ml) under ice cooling. The mixture was stirred for 30 minutes and to the mixture were added cold dichloromethane (5 ml), an aqueous saturated sodium bicarbonate (2 ml) solution and 1-(triphenylphosphoranylidene)-2-propanone (126 mg) in dichloromethane (2 ml). The mixture was stirred at 10°C for 2 hours. The organic layer was separated, dried and concentrated in vacuo. The residue was purified by column chromatography on silica gel and the obtained oil was crystallized from diisopropyl ether to give 8-(4-fluorophenyl)-4-methyl-7-(pyridin-4-yl)pyrazolo-
25 [5,1-c][1,2,4]triazine (41 mg).

mp : 202.5-204.0°C

NMR (CDCl₃, δ) : 2.91 (3H, s), 7.18 (2H, t, J=9Hz),
7.62 (2H, dd, J=5Hz and 9Hz), 7.68 (2H, d,
J=6Hz), 8.70 (2H, d, J=6Hz), 8.79 (1H, s)

30

Preparation 9

The following compounds were obtained according to a similar manner to that of Preparation 8.

35 (1) 8-(4-Fluorophenyl)-7-(pyridin-4-yl)pyrazolo[5,1-c]-

[1,2,4]triazine

mp : 180-182°C

NMR (CDCl₃, δ) : 7.20 (2H, t, J=9Hz), 7.55-7.70 (4H, m), 8.59 (1H, d, J=5Hz), 8.70 (2H, d, J=6Hz), 8.90 (1H, d, J=5Hz)

(2) 7-(4-Fluorophenyl)-4-methyl-8-(pyridin-4-yl)pyrazolo-[5,1-c][1,2,4]triazine

mp : 220-223°C (dec.)

NMR (CDCl₃, δ) : 2.90 (3H, s), 7.17 (2H, t, J=9Hz), 7.60-7.75 (4H, m), 8.67 (2H, d, J=6Hz), 8.81 (1H, m)

(3) 7-(4-Fluorophenyl)-8-(pyridin-4-yl)pyrazolo[5,1-c]-[1,2,4]triazine

NMR (CDCl₃, δ) : 7.18 (2H, t, J=9Hz), 7.60-7.75 (4H, m), 8.59 (1H, d, J=4Hz), 8.68 (2H, d, J=6Hz), 8.93 (1H, d, J=4Hz)

Preparation 10

The following compounds were obtained according to a similar manner to that of Preparation 1.

(1) 2-(2-Chloropyridin-4-yl)-1-(4-fluorophenyl)ethan-1-one

mp : 99-103°C

NMR (CDCl₃, δ) : 4.28 (2H, s), 7.11-7.22 (3H, m), 7.27 (1H, s), 8.03 (2H, dd, J=6Hz and 9Hz), 8.37 (1H, d, J=6Hz)

(2) 2-(2-Bromopyridin-4-yl)-1-(4-fluorophenyl)ethan-1-one

mp : 100-104°C

NMR (CDCl₃, δ) : 4.25 (2H, s), 7.14-7.24 (3H, m), 7.40 (1H, s), 8.02 (2H, dd, J=6Hz and 9Hz), 8.35 (1H, d, J=6Hz)

Preparation 11

The following compounds were obtained according to similar manners to those of Preparation 2 and 3.

- 5 (1) 4-(2-Chloropyridin-4-yl)-5-(4-fluorophenyl)isoxazole
mp : 94-96°C
NMR (CDCl₃, δ) : 7.17 (2H, t, J=9Hz), 7.22 (1H, d,
J=6Hz), 7.36 (1H, s), 7.62 (2H, dd, J=6Hz and
9Hz), 8.41 (1H, d, J=6Hz), 8.43 (1H, s)

10

- (2) 4-(2-Bromopyridin-4-yl)-5-(4-fluorophenyl)isoxazole
mp : 136-138°C
NMR (CDCl₃, δ) : 7.28 (2H, t, J=9Hz), 7.24 (1H, d,
J=6Hz), 7.53 (1H, s), 7.63 (2H, dd, J=6Hz and
15 9Hz), 8.39 (1H, d, J=6Hz), 8.44 (1H, s)

Preparation 12

The following compounds were obtained according to similar manners to those of Preparation 4 and 6.

20

- (1) 2-(2-Chloropyridin-4-yl)-3-(4-fluorophenyl)-3-oxopropanenitrile
mp : 204-206°C (dec.)
NMR (CDCl₃ + CD₃OD, δ) : 7.13 (2H, t, J=9Hz), 7.72
25 (2H, dd, J=6Hz and 9Hz), 7.78-7.90 (2H, m), 8.08
(1H, m)

25

- (2) 2-(2-Bromopyridin-4-yl)-3-(4-fluorophenyl)-3-oxopropanenitrile
mp : 217-219°C (dec.)
NMR (CDCl₃ + CD₃OD, δ) : 7.13 (2H, t, J=9Hz), 7.73
30 (2H, dd, J=6Hz and 9Hz), 7.79-7.90 (2H, m), 8.23
(1H, m)

30

35

Preparation 13

The following compounds were obtained according to similar manners to those of Preparation 5 and 7.

- 5 (1) 5-Amino-4-(2-chloropyridin-4-yl)-3-(4-fluorophenyl)-pyrazole
mp : 213-216°C
NMR (CDCl₃ + CD₃OD, δ) : 7.03-7.14 (3H, m),
7.29-7.38 (3H, m), 8.23 (1H, d, J=6Hz)
- 10 (2) 5-Amino-4-(2-bromopyridin-4-yl)-3-(4-fluorophenyl)-pyrazole
mp : 213-215°C
NMR (CDCl₃ + CD₃OD, δ) : 7.01-7.14 (3H, m),
15 7.28-7.47 (3H, m), 8.24 (1H, d, J=6Hz)

Preparation 14

The following compounds were obtained according to a similar manner to that of Preparation 8.

- 20 (1) 8-(2-Chloropyridin-4-yl)-7-(4-fluorophenyl)pyrazolo-[5,1-c][1,2,4]triazine
mp : >250°C
NMR (DMSO-d₆, δ) : 7.40 (2H, t, J=9Hz), 7.58 (1H, d, J=6Hz),
25 7.70 (2H, dd, J=6Hz and 9Hz), 7.80 (1H, s), 8.49 (1H, d, J=6Hz), 9.20 (1H, d, J=5Hz),
9.40 (1H, d, J=5Hz)
- 30 (2) 8-(2-Bromopyridin-4-yl)-7-(4-fluorophenyl)pyrazolo-[5,1-c][1,2,4]triazine
mp : 258°C (dec.)
NMR (DMSO-d₆, δ) : 7.42 (2H, t, J=9Hz), 7.58 (1H, d, J=6Hz),
35 7.71 (2H, dd, J=6Hz and 9Hz), 7.80 (1H, s), 8.50 (1H, d, J=6Hz), 9.20 (1H, d, J=5Hz),
9.43 (1H, d, J=5Hz)

(3) 7-(4-Fluorophenyl)-8-(2-fluoropyridin-4-yl)pyrazolo-
[5,1-c][1,2,4]triazine

mp : 240-242°C

NMR (CDCl₃:CD₃OD = 9:1, δ) : 7.23 (2H, t, J=9Hz),
5 7.42 (1H, s), 7.57 (1H, d, J=6Hz),
7.69 (2H, dd, J=6Hz and 9Hz),
8.24 (1H, d, J=6Hz), 8.78 (1H, d, J=4Hz),
9.01 (1H, d, J=4Hz)

10 Preparation 15

To a suspension of 7-(4-fluorophenyl)-8-(2-
fluoropyridin-4-yl)pyrazolo[5,1-c][1,2,4]triazine (350 mg)
in methanol (2 ml) was added conc. sulfuric acid (0.32 ml)
dropwise. The mixture was refluxed for 1 hour, cooled and
15 poured into cold water. The aqueous solution was
neutralized with an aqueous saturated sodium bicarbonate
solution and the separated oil was extracted with
dichloromethane. The extract was washed with brine, dried
and concentrated in vacuo. The residue was purified by
20 column chromatography on silica gel and the obtained oil
was crystallized from methanol to give 7-(4-fluorophenyl)-
8-(2-methoxypyridin-4-yl)pyrazolo[5,1-c][1,2,4]triazine
(220 mg).

mp : 223-225°C

25 NMR (CDCl₃:CD₃OD = 9:1, δ) : 3.99 (3H, s),
7.10-7.25 (4H, m), 7.69 (2H, dd, J=6Hz and 9Hz),
8.21 (1H, d, J=6Hz), 8.68 (1H, d, J=4Hz),
8.93 (1H, d, J=4Hz)

30

35

Example 1

To a suspension of 7-(4-fluorophenyl)-8-(pyridin-4-yl)pyrazolo[5,1-c][1,2,4]triazine (2.2 g) in methanol (20 ml) was added sodium cyanoborohydride (480 mg). The pH of the mixture was maintained at 3 to 4 for 2 hours with 1N hydrochloric acid. The procedure was repeated three additional times to completely finish the reduction. Then, the mixture was concentrated in vacuo and the residue was dissolved in 2N hydrochloric acid. The mixture was stirred at 80°C for 30 minutes and cooled. The solution was neutralized with an aqueous saturated sodium bicarbonate solution. The separated solid was collected, washed with water and methanol and dried to give 7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (2.06 g).

mp : 233-235°C

NMR (CDCl₃:CD₃OD = 9:1, δ) : 3.37 (2H, t, J=6Hz),
4.17 (2H, t, J=6Hz), 7.13 (2H, t, J=9Hz),
7.30-7.50 (4H, m), 8.24 (2H, d, J=6Hz)

Example 2

The following compounds were obtained according to a similar manner to that of Example 1.

- (1) 7-(4-Fluorophenyl)-4-methyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

mp : 219-221°C

NMR (CDCl₃:CD₃OD = 9:1, δ) : 1.60 (3H, d, J=7Hz),
3.05 (1H, dd, J=6Hz and 14Hz), 3.38 (1H, dd,
J=4Hz and 14Hz), 4.33 (1H, m), 7.06 (2H, t,
J=9Hz), 7.12 (2H, d, J=6Hz), 7.40 (2H, dd,
J=6Hz and 9Hz), 8.37 (2H, d, J=6Hz)

- (2) 8-(4-Fluorophenyl)-7-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

mp : >250°C

NMR (CDCl₃, δ) : 3.38 (2H, q, J=6Hz), 3.60 (1H, m),
4.21 (2H, t, J=6Hz), 5.47 (1H, d, J=5Hz), 7.06
(2H, t, J=9Hz), 7.19 (2H, dd, J=6Hz and 9Hz),
7.35 (2H, d, J=6Hz), 8.49 (2H, d, J=6Hz)

Example 3

To a solution of 7-(4-fluorophenyl)-8-(pyridin-4-yl)-
1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (207 mg)
in acetic acid (2 ml) was added acetic anhydride (75 mg)
with ice cooling. The solution was stirred at ambient
temperature for 1 hour and concentrated in vacuo. The
residue was dissolved in water (3 ml) and the solution was
neutralized with an aqueous saturated sodium bicarbonate
solution. The separated oil was extracted with
dichloromethane and the extract was dried and concentrated
in vacuo. The residue was crystallized from ethyl acetate
to give 2-acetyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-
1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (195 mg).

mp : 216-218°C

NMR (CDCl₃:CD₃OD = 9:1, δ) : 2.28 (3H, s), 4.13 (2H,
t, J=6Hz), 4.26 (2H, t, J=6Hz), 7.05 (2H, t,
J=9Hz), 7.27 (2H, d, J=6Hz), 7.40 (2H, dd,
J=6Hz and 9Hz), 8.42 (2H, d, J=6Hz)

Example 4

The following compounds were obtained according to a
similar manner to that of Example 3.

(1) 2-Acetyl-8-(4-fluorophenyl)-7-(pyridin-4-yl)-1,2,3,4-
tetrahydropyrazolo[5,1-c][1,2,4]triazine

mp : 115-120°C

NMR (CDCl₃, δ) : 2.28 (3H, s), 4.14 (2H, t, J=6Hz),
4.28 (2H, t, J=6Hz), 6.08 (1H, s), 7.09 (2H, t,
J=9Hz), 7.23 (2H, dd, J=6Hz and 9Hz), 7.35 (2H,

d, J=6Hz), 8.49 (2H, d, J=6Hz)

(2) 7-(4-Fluorophenyl)-2-formyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

5 mp : 233-235°C

NMR (CDCl₃, δ) : 4.10-4.20 (2H, m), 4.25-4.40 (2H, m), 6.50 (1H, br s), 7.05 (2H, t, J=9Hz), 7.15 (2H, d, J=6Hz), 7.40 (2H, dd, J=6Hz and 9Hz), 8.45 (2H, d, J=6Hz), 8.55 (1H, s)

10

Example 5

To a mixture of 7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (148 mg) and triethylamine (101 mg) in dry dichloromethane was added acetic anhydride (54 mg). The reaction mixture was stirred at ambient temperature for 4 hours and then, to the mixture was added methanol (1 ml). After standing for 30 minutes, the mixture was concentrated in vacuo. The residue was purified by column chromatography on silica gel. The first fraction was concentrated in vacuo and the obtained oil was crystallized from a mixture of diethyl ether and n-hexane to give 1,2-diacetyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo-

25

mp : 162-164°C

NMR (CDCl₃, δ) : 2.11 (3H, s), 2.32 (3H, s), 3.40 (1H, m), 4.20-4.45 (2H, m), 5.07 (1H, dd, J=6Hz and 14Hz), 7.10 (2H, t, J=9Hz), 7.14 (2H, d, J=6Hz), 7.33 (2H, dd, J=6Hz and 9Hz), 8.58 (2H, d, J=6Hz)

30

The second fraction was concentrated in vacuo and the obtained oil was crystallized from ethyl acetate to give 2-acetyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (101 mg).

35

mp : 216-218°C

NMR ($\text{CDCl}_3:\text{CD}_3\text{OD} = 9:1$, δ) : 2.28 (3H, s), 4.12 (2H, t, $J=6\text{Hz}$), 4.25 (2H, t, $J=6\text{Hz}$), 7.07 (2H, t, $J=9\text{Hz}$), 7.20 (2H, d, $J=6\text{Hz}$), 7.40 (2H, dd, $J=6\text{Hz}$ and 9Hz), 8.42 (2H, d, $J=6\text{Hz}$)

5

Example 6

The following two compounds were obtained by reacting 7-(4-fluorophenyl)-4-methyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydro[5,1-c][1,2,4]triazine according to a similar manner to that of Example 5.

10

2-Acetyl-7-(4-fluorophenyl)-4-methyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine
mp : 247-249°C

15

NMR ($\text{CDCl}_3:\text{CD}_3\text{OD} = 9:1$, δ) : 1.60 (3H, d, $J=7\text{Hz}$), 2.30 (3H, s), 3.93 (1H, dd, $J=6\text{Hz}$ and 13Hz), 4.10 (1H, dd, $J=5\text{Hz}$ and 13Hz), 4.46 (1H, m), 7.06 (2H, t, $J=9\text{Hz}$), 7.21 (2H, d, $J=6\text{Hz}$), 7.41 (2H, dd, $J=6\text{Hz}$ and 9Hz), 8.42 (2H, d, $J=6\text{Hz}$)

20

1,2-Diacetyl-7-(4-fluorophenyl)-4-methyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine
mp : 193-194°C

25

NMR (CDCl_3 , δ) : 1.71 (3H, d, $J=7\text{Hz}$), 2.12 (3H, s), 2.31 (3H, s), 3.00 (1H, dd, $J=11\text{Hz}$ and 13Hz), 4.43 (1H, m), 5.05 (1H, dd, $J=6\text{Hz}$ and 13Hz), 7.00 (2H, t, $J=9\text{Hz}$), 7.13 (2H, d, $J=6\text{Hz}$), 7.35 (2H, dd, $J=6\text{Hz}$ and 9Hz), 8.58 (2H, d, $J=6\text{Hz}$)

30

Example 7

To a mixture of 7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (100 mg, 0.339 mmol) and pyridine (54 mg, 0.678 mmol) in N-methyl-2-pyrrolidone (1.5 ml) was added acetoxyacetyl chloride (60 mg, 0.441 mmol) in N-methyl-2-pyrrolidone

35

(0.5 ml) under nitrogen atmosphere with ice cooling. After stirring for 30 minutes, the reaction mixture was diluted with an aqueous saturated sodium bicarbonate solution, then extracted with ethyl acetate. The organic phase was washed with water and brine, dried over sodium sulfate, and concentrated in vacuo. The residue was purified by chromatography on silica gel (eluent:dichloromethane/methanol; 100/1-20/1) and the obtained amorphous product was crystallized from diisopropyl ether to give 2-acetoxyacetyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo-

mp : 121°C (dec.)

NMR (DMSO-d₆, δ) : 2.10 (3H, s), 3.95-4.05 (2H, m), 4.10-4.20 (2H, m), 4.90 (2H, s), 7.15-7.30 (4H, m), 7.35-7.45 (2H, m), 8.45 (2H, d, J=6Hz), 8.70 (1H, s)

Example 8

The following compounds were obtained according to a similar manner to that of Example 7.

(1) 7-(4-Fluorophenyl)-2-methylsulfonyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

mp : 133-135°C

NMR (CDCl₃:CD₃OD = 9:1, δ) : 3.16 (3H, s), 4.03 (2H, t, J=6Hz), 4.33 (2H, t, J=6Hz), 7.08 (2H, t, J=9Hz), 7.30-7.45 (4H, m), 8.40 (2H, d, J=6Hz)

(2) 7-(4-Fluorophenyl)-2-methoxycarbonyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

mp : 215-216°C

NMR (DMSO-d₆, δ) : 3.65 (3H, s), 3.90-4.00 (2H, m), 4.10-4.25 (2H, m), 7.15 (2H, d, J=6Hz), 7.20 (2H, t, J=9Hz), 7.40 (2H, dd, J=6Hz and 9Hz),

3.45 (2H, d, J=6Hz), 8.55 (1H, s)

- 5 (3) 7-(4-Fluorophenyl)-8-(pyridin-4-yl)-2-[4-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine
mp : 207-209°C
NMR (DMSO-d₆, δ) : 4.10-4.40 (4H, m), 6.75-6.90 (2H, m), 7.10-7.45 (4H, m), 7.75-7.85 (4H, m), 8.20-8.35 (2H, m)
- 10 (4) 2-Cinnamoyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine
mp : 228-230°C
NMR (CDCl₃, δ) : 4.25-4.40 (4H, m), 6.25 (1H, br s), 7.05 (2H, t, J=9Hz), 7.20 (2H, d, J=6Hz), 7.30-7.60 (8H, m), 7.80 (1H, d, J=15Hz), 8.55 (2H, d, J=6Hz)
- 15 (5) 2-Benzoyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine
mp : 141°C (dec.)
NMR (CDCl₃, δ) : 4.20-4.40 (4H, m), 6.85-7.10 (4H, m), 7.40 (2H, dd, J=6Hz and 9Hz), 7.45-7.65 (5H, m), 8.30-8.45 (2H, m)
- 20 (6) 2-[4-(Acetoxy)benzoyl]-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine
mp : 148°C (dec.)
NMR (CDCl₃, δ) : 2.35 (3H, s), 4.25-4.40 (4H, m), 6.90-7.10 (4H, m), 7.20 (2H, t, J=9Hz), 7.40 (2H, dd, J=6Hz and 9Hz), 7.65 (2H, d, J=9Hz), 8.40 (2H, d, J=6Hz)
- 25 (7) 2-(3-Carboxypropanoyl)-7-(4-fluorophenyl)-8-(pyridin-
- 30
- 35

4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]-
triazine

mp : 214-215°C

5 NMR (DMSO-d₆, δ) : 2.45 (2H, t, J=6Hz), 2.72 (2H, t, J=6Hz), 4.02 (2H, t, J=5Hz), 4.15 (2H, t, J=5Hz), 7.10-7.30 (4H, m), 7.40 (2H, dd, J=6Hz and 9Hz), 8.49 (2H, d, J=6Hz), 8.70 (1H, s)

10 (8) 2-Chloroacetyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-
1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

NMR (CDCl₃, δ) : 4.15-4.25 (2H, m), 4.25-4.35 (2H, m), 4.40 (2H, s), 6.45 (1H, s), 7.00 (2H, t, J=9Hz), 7.15 (2H, d, J=6Hz), 7.40 (2H, dd, J=6Hz and 9Hz), 8.50 (2H, d, J=6Hz)

15

(9) 7-(4-Fluorophenyl)-2-methoxyacetyl-8-(pyridin-4-yl)-
1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

mp : 219°C (dec.)

20 NMR (CDCl₃, δ) : 3.45 (3H, s), 4.10-4.25 (2H, m), 4.25-4.35 (2H, m), 4.40 (2H, s), 6.45 (1H, br s), 7.05 (2H, t, J=9Hz), 7.15 (2H, d, J=6Hz), 7.40 (2H, dd, J=6Hz and 9Hz), 8.50 (2H, d, J=6Hz)

25 (10) 7-(4-Fluorophenyl)-2-pivaloyl-8-(pyridin-4-yl)-
1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

mp : 248-250°C

30 NMR (CDCl₃, δ) : 1.30 (9H, s), 4.10-4.20 (2H, m), 4.22-4.32 (2H, m), 6.28 (1H, br s), 7.04 (2H, t, J=9Hz), 7.14 (2H, d, J=6Hz), 7.41 (2H, dd, J=6Hz and 9Hz), 8.50 (2H, d, J=6Hz)

(11) 2-Cyclohexylcarbonyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-
1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

35 mp : 209-211°C

NMR (CDCl₃, δ) : 1.20-1.60 (6H, m), 1.70-1.90 (4H, m), 2.95-3.10 (1H, m), 4.10-4.30 (4H, m), 6.15 (1H, br s), 7.05 (2H, t, J=9Hz), 7.15 (2H, d, J=6Hz), 7.40 (2H, dd, J=6Hz and 9Hz), 8.50 (2H, d, J=6Hz)

5

(12) 2-Cyclohexylcarbonyloxyacetyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c]-[1,2,4]triazine

10

mp : 178-181°C

NMR (CDCl₃, δ) : 1.20-1.83 (8H, m), 1.90-2.05 (2H, m), 2.35-2.52 (1H, m), 4.10-4.20 (2H, m), 4.24-4.35 (2H, m), 5.00 (2H, s), 6.54 (1H, s), 7.05 (2H, t, J=9Hz), 7.12 (2H, d, J=6Hz), 7.40 (2H, dd, J=6Hz and 9Hz), 8.50 (2H, d, J=6Hz)

15

(13) 2-Cyclopropylcarbonyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]-triazine

20

mp : 192-194°C

NMR (CDCl₃, δ) : 0.80-1.15 (4H, m), 2.52 (1H, m), 4.10-4.35 (4H, m), 6.52 (1H, s), 7.04 (2H, t, J=9Hz), 7.17 (2H, d, J=6Hz), 7.40 (2H, dd, J=6Hz and 9Hz), 8.49 (2H, d, J=6Hz)

25

(14) 2-(3,3-Dimethylbutyryl)-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c]-[1,2,4]triazine

mp : 120°C (dec.)

30

NMR (CDCl₃, δ) : 1.03 (9H, s), 2.60 (2H, s), 4.14-4.30 (4H, m), 6.08 (1H, s), 7.03 (2H, t, J=9Hz), 7.17 (2H, d, J=6Hz), 7.40 (2H, dd, J=6Hz and 9Hz), 8.50 (2H, d, J=6Hz)

35

(15) 7-(4-Fluorophenyl)-2-isopropoxyloxycarbonyl-8-(pyridin-

4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]-
triazine

mp : 170-172°C

5 NMR (CDCl₃, δ) : 1.32 (6H, d, J=6Hz), 4.10 (2H, t,
J=5Hz), 4.25 (2H, t, J=5Hz), 5.01 (1H, quint,
J=6Hz), 6.60 (1H, br s), 7.03 (2H, t, J=9Hz),
7.16 (2H, d, J=6Hz), 7.40 (2H, dd, J=6Hz and
9Hz), 8.51 (2H, d, J=6Hz)

10 (16) 2-(3-Chloro-2,2-dimethylpropionyl)-7-(4-
fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydro-
pyrazolo[5,1-c][1,2,4]triazine

mp : 188-189°C

15 NMR (CDCl₃, δ) : 1.20 (6H, s), 3.20 (2H, s), 4.14
(2H, t, J=5.5Hz), 4.32 (2H, t, J=5.5Hz), 7.00
(2H, t, J=9Hz), 7.18 (2H, d, J=6Hz), 7.30 (2H,
dd, J=6Hz and 9Hz), 8.58 (2H, d, J=6Hz)

20 (17) 2-(2,2-Dimethylbutyryl)-7-(4-fluorophenyl)-8-
(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c]-
[1,2,4]triazine

mp : 204°C (dec.)

25 NMR (CDCl₃, δ) : 0.79 (3H, t, J=9Hz), 1.27 (6H, s),
1.70 (2H, q, J=9Hz), 4.12-4.21 (2H, m),
4.24-4.33 (2H, m), 6.20 (1H, br s), 7.04 (2H, t,
J=9Hz), 7.13 (2H, d, J=6Hz), 7.43 (2H, dd, J=6Hz
and 9Hz), 8.52 (2H, d, J=6Hz)

30 (18) 2-Ethoxalyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-
1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

mp : 174-176°C

35 NMR (CDCl₃, δ) : 1.29 (3H, t, J=7Hz), 4.18 (2H, t,
J=6Hz), 4.25-4.45 (4H, m), 6.95-7.15 (4H, m),
7.39 (2H, dd, J=6Hz and 9Hz), 8.37 (2H, d,
J=6Hz)

(19) 7-(4-Fluorophenyl)-2-[(3-methoxyphenyl)glyoxyloyl]-
8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c]-
[1,2,4]triazine hydrochloride

mp : 270-179°C (dec.)

NMR (CDCl₃, + CD₃OD, δ) : 3.80 (3H, s), 4.30-4.40
(2H, m), 4.40-4.50 (2H, m), 7.07-7.19 (3H, m),
7.25-7.40 (7H, m), 8.22 (2H, d, J=6Hz)

(20) 2-Acetoxyacetyl-8-(4-fluorophenyl)-7-(pyridin-4-yl)-
1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

mp : 231-232°C

NMR (CDCl₃:CD₃OD = 9:1, δ) : 2.18 (3H, s), 4.13 (2H,
t, J=6Hz), 4.30 (2H, t, J=6Hz), 4.92 (2H, s),
7.09 (2H, t, J=9Hz), 7.21 (2H, dd, J=6Hz and
9Hz), 7.36 (2H, d, J=6Hz), 8.48 (2H, d, J=6Hz)

Example 9

A mixture of 7-(4-fluorophenyl)-8-(pyridin-4-yl)-
1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (118 mg)
and ethyl isocyanate (30 mg) in dichloromethane (2 ml) was
stirred at ambient temperature for 1 hour. The mixture
was concentrated in vacuo and the residue was crystallized
from ethyl acetate to give 2-ethylcarbamoyl-7-(4-
fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo-
[5,1-c][1,2,4]triazine (120 mg).

mp : 235-240°C

NMR (CDCl₃:CD₃OD = 9:1, δ) : 1.12 (3H, t, J=7Hz),
3.25 (2H, q, J=7Hz), 4.07 (2H, t, J=6Hz), 4.20
(2H, t, J=6Hz), 7.04 (2H, t, J=9Hz), 7.14 (2H,
d, J=6Hz), 7.40 (2H, dd, J=6Hz and 9Hz), 8.47
(2H, d, J=6Hz)

Example 10

The following compounds were obtained according to a
similar manner to that of Example 9.

(1) 7-(4-Fluorophenyl)-2-[phenyl(thiocarbamoyl)]-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c]-[1,2,4]triazine

mp : 197-200°C

5 NMR (CDCl₃, δ) : 4.40 (2H, t, J=6Hz), 4.83 (2H, t, J=6Hz), 7.06 (2H, t, J=9Hz), 7.15-7.50 (10H, m), 8.48 (2H, d, J=6Hz), 9.20 (1H, s)

(2) 7-(4-Fluorophenyl)-2-phenylcarbamoyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

10

mp : 180-182°C

NMR (CDCl₃, δ) : 4.17 (2H, t, J=6Hz), 4.28 (2H, t, J=6Hz), 6.95-7.10 (3H, m), 7.15-7.45 (9H, m), 8.12 (1H, s), 8.51 (2H, d, J=6Hz)

15

(3) 2-Carbamoyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

mp : 141-145°C

20 NMR (CDCl₃:CD₃OD = 9:1, δ) : 4.06 (2H, t, J=6Hz), 4.23 (2H, t, J=6Hz), 7.07 (2H, t, J=9Hz), 7.25 (2H, d, J=6Hz), 7.40 (2H, dd, J=6Hz and 9Hz), 8.43 (2H, d, J=6Hz)

Example 11

25

A mixture of 7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (74 mg) and N,N'-disuccinimidylcarbonate (77 mg) in dry

N,N-dimethylformamide (2 ml) was stirred at ambient temperature for 1 hour. To the mixture was added

30

diethylamine (0.13 ml) and the mixture was stirred at ambient temperature for 3 hours. The reaction mixture was poured into cold water and the separated oil was extracted with ethyl acetate. The extract was washed with brine, dried and concentrated in vacuo. The residue was

35

crystallized from ethyl acetate to give

2-diethylcarbamoyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-
1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (80 mg).

mp : 223-226°C

NMR (CDCl₃:CD₃OD = 9:1, δ) : 1.01 (6H, t, J=7Hz),
3.27 (4H, q, J=7Hz), 3.84 (2H, t, J=6Hz), 4.35
(2H, t, J=6Hz), 7.03 (2H, t, J=9Hz), 7.15 (2H,
d, J=6Hz), 7.40 (2H, dd, J=6Hz and 9Hz), 8.40
(2H, d, J=6Hz)

10 Example 12

The following compounds were obtained according to a
similar manner to that of Example 11.

(1) 7-(4-Fluorophenyl)-2-morpholinocarbonyl-8-(pyridin-4-
yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

mp : 232-234°C

NMR (CDCl₃:CD₃OD = 9:1, δ) : 3.52 (4H, t, J=6Hz),
3.63 (4H, t, J=6Hz), 3.86 (2H, t, J=6Hz), 4.35
(2H, t, J=6Hz), 7.06 (2H, t, J=9Hz), 7.17 (2H,
d, J=6Hz), 7.41 (2H, dd, J=6Hz and 9Hz), 8.41
(2H, d, J=6Hz)

(2) 2-Bis(2-hydroxyethyl)carbamoyl-7-(4-fluorophenyl)-8-
(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c]-
[1,2,4]triazine

mp : 118-121°C

NMR (CDCl₃:CD₃OD = 1:1, δ) : 3.50 (4H, t, J=6Hz),
3.62 (4H, t, J=6Hz), 3.89 (2H, t, J=6Hz), 7.07
(2H, t, J=9Hz), 7.18 (2H, d, J=6Hz), 7.38 (2H,
dd, J=6Hz and 9Hz), 8.49 (2H, d, J=6Hz)

(3) 2-Cyclohexylcarbamoyl-7-(4-fluorophenyl)-8-(pyridin-
4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]-
triazine

mp : 181-183°C

5 NMR (CDCl₃, δ) : 1.00-1.50 (4H, m), 1.50-1.80 (4H, m), 1.80-2.00 (2H, m), 3.60 (1H, m), 4.07 (2H, t, J=6Hz), 4.23 (2H, t, J=6Hz), 5.91 (1H, d, J=8Hz), 6.10 (1H, s), 7.03 (2H, t, J=9Hz), 7.11 (2H, d, J=6Hz), 7.42 (2H, dd, J=6Hz and 9Hz), 8.53 (2H, d, J=6Hz)

10 (4) 7-(4-Fluorophenyl)-2-(piperidin-1-yl)carbamoyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c]-[1,2,4]triazine

mp : 140-141°C

15 NMR (CDCl₃:CD₃OD = 9:1, δ) : 1.39 (2H, m), 1.65 (4H, m), 2.70 (4H, t, J=5Hz), 4.30 (2H, t, J=6Hz), 4.23 (2H, t, J=6Hz), 7.07 (2H, t, J=9Hz), 7.15 (2H, d, J=6Hz), 7.38 (2H, dd, J=6Hz and 9Hz), 8.47 (2H, d, J=6Hz)

20 (5) 7-(4-Fluorophenyl)-2-methoxycarbamoyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

mp : 209-210°C

25 NMR (CDCl₃:CD₃OD = 9:1, δ) : 3.73 (3H, s), 4.07 (2H, t, J=6Hz), 4.26 (2H, t, J=6Hz), 7.07 (2H, t, J=9Hz), 7.18 (2H, d, J=6Hz), 7.40 (2H, dd, J=6Hz and 9Hz), 8.42 (2H, d, J=6Hz)

(6) 7-(4-Fluorophenyl)-2-(2-hydroxyethylcarbamoyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c]-[1,2,4]triazine

mp : 139-140°C (dec.)

30 NMR (DMSO-d₆, δ) : 3.13 (2H, m), 3.38 (2H, m), 3.85 (2H, t, J=6Hz), 4.07 (2H, t, J=6Hz), 4.65 (1H, t, J=5Hz), 6.85 (1H, t, J=5Hz), 7.20 (2H, t, J=9Hz), 7.27 (2H, d, J=5Hz), 7.37 (2H, dd, J=6Hz and 9Hz), 8.47 (2H, d, J=5Hz), 8.50 (1H, s)

35

Example 13

A mixture of 3-indolylacetic acid (57 mg, 0.325 mmol), 3-(3-dimethylaminopropyl)-1-ethylcarbodiimide (50 mg, 0.325 mmol) and 1-hydroxybenzotriazole (44 mg, 0.325 mmol) in N,N-dimethylformamide (0.6 ml) was stirred for 1 hour at ambient temperature. Then to the mixture was added 7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (80 mg, 0.271 mmol) in N,N-dimethylformamide (1 ml). After stirring for 2 hours, the mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with water and brine, dried over sodium sulfate and concentrated in vacuo. The residue was purified by crystallization from ethyl acetate to give 7-(4-fluorophenyl)-2-(3-indolylacetyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (87 mg).
mp : 212-214°C
NMR (CDCl₃ + CD₃OD, δ) : 4.02-4.13 (4H, m), 4.18-4.27 (2H, m), 6.96-7.24 (7H, m), 7.32-7.42 (3H, m), 7.58 (1H, d, J=8Hz), 8.37 (2H, d, J=6Hz)

Example 14

The following compounds were obtained according to a similar manner to that of Example 13.

25

- (1) 2-tert-Butoxycarbonylaminoacetyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

NMR (CDCl₃, δ) : 1.45 (9H, s), 4.10-4.20 (2H, m), 4.20-4.35 (4H, m), 5.20-5.30 (1H, m), 6.70 (1H, br s), 7.05 (2H, t, J=9Hz), 7.15 (2H, d, J=6Hz), 7.35 (2H, dd, J=6Hz and 9Hz), 8.45 (2H, d, J=6Hz)

35

- (2) 7-(4-Fluorophenyl)-2-(2-methoxy-2-methylpropionyl)-

8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c]-
[1,2,4]triazine

mp : 114-116°C

5 NMR (CDCl₃, δ) : 1.50 (6H, s), 3.28 (3H, s),
4.20-4.36 (3H, m), 4.64-4.83 (1H, m), 7.03 (2H,
t, J=9Hz), 7.10 (2H, d, J=6Hz), 7.42 (2H, d,
J=6.9Hz), 8.50-8.56 (3H, m)

10 (3) 7-(4-Fluorophenyl)-2-[(R)-(methoxy)(phenyl)acetyl]-8-
(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c]-
[1,2,4]triazine

mp : 213-215°C

15 NMR (CDCl₃, δ) : 3.34 (3H, s), 3.70-3.88 (1H, m),
4.20-4.30 (2H, m), 4.45-4.58 (1H, m), 5.77 (1H,
s), 5.88 (1H, s), 6.98-7.08 (4H, m), 7.27-7.33
(5H, m), 7.38 (2H, dd, J=6Hz and 9Hz), 8.56 (2H,
d, J=6Hz)

20 (4) 2-[(Biphenyl-4-yl)acetyl]-7-(4-fluorophenyl)-8-
(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c]-
[1,2,4]triazine

mp : 153°C

25 NMR (CDCl₃, δ) : 3.98 (2H, s), 4.12-4.20 (2H, m),
4.20-4.32 (2H, m), 6.04 (1H, s), 7.03 (2H, t,
J=9Hz), 7.08 (2H, d, J=6Hz), 7.23-7.57 (11H, m),
8.50 (2H, d, J=6Hz)

30 (5) 2-[(2,6-Dichlorophenyl)acetyl]-7-(4-fluorophenyl)-8-
(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c]-
[1,2,4]triazine

mp : >250°C

35 NMR (CDCl₃ + CD₃OD, δ) : 4.15-4.24 (2H, m),
4.24-4.37 (4H, m), 7.06 (2H, t, J=9Hz),
7.10-7.33 (5H, m), 7.43 (2H, dd, J=6Hz and 9Hz),
8.48 (2H, d, J=6Hz)

- (6) 2-(N,N-Dimethylaminoacetyl)-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c]-[1,2,4]triazine dihydrochloride

mp : >250°C

5 NMR (DMSO-d₆, δ) : 2.82 (6H, s), 4.10 (2H, t, J=5Hz), 4.25 (2H, t, J=5Hz), 4.40 (2H, s), 7.30 (2H, t, J=9Hz), 7.47 (2H, dd, J=6Hz and 9Hz), 7.79 (2H, d, J=6Hz), 8.70 (2H, d, J=6Hz), 10.12 (1H, s)

10

- (7) 7-(4-Fluorophenyl)-2-(phenylthioacetyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]-triazine hydrochloride

mp : 235-238°C

15 NMR (DMSO-d₆, δ) : 3.95-4.20 (6H, m), 7.10-7.40 (7H, m), 7.49 (2H, dd, J=6Hz and 9Hz), 7.69 (2H, d, J=6Hz), 8.68 (2H, d, J=6Hz), 9.69 (1H, s)

- (8) 7-(4-Fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydro-2-[(3-trifluoromethylphenyl)acetyl]-pyrazolo[5,1-c][1,2,4]triazine hydrochloride

mp : 254°C (dec.)

20 NMR (CDCl₃ + CD₃OD, δ) : 4.05 (2H, s), 4.17-4.39 (4H, m), 7.13 (2H, t, J=9Hz), 7.24-7.42 (6H, m), 7.62-7.74 (2H, m), 8.32-8.50 (2H, m)

25

- (9) 2-[(3,4-Dimethoxyphenyl)acetyl]-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c]-[1,2,4]triazine hydrochloride

30 NMR (CDCl₃, δ) : 3.73 (6H, s), 3.96 (2H, s), 4.18-4.26 (4H, m), 6.62 (1H, s), 6.64 (2H, d, J=8Hz), 7.13 (2H, t, J=9Hz), 7.37 (2H, dd, J=6Hz and 9Hz), 7.70-7.77 (2H, m), 8.10-8.20 (2H, m), 9.60 (1H, br s)

35

(10) 2-(Acetylaminoacetyl)-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]-triazine hydrochloride

mp : 239-243°C

5 NMR (DMSO-d₆, δ) : 1.87 (3H, s), 4.01 (2H, t, J=5Hz), 4.12 (2H, d, J=6Hz), 4.20 (2H, t, J=5Hz), 7.30 (2H, t, J=9Hz), 7.48 (2H, dd, J=6Hz and 9Hz), 7.69 (2H, d, J=6Hz), 8.11 (1H, t, J=6Hz), 8.70 (2H, d, J=6Hz), 9.64 (1H, s)

10

Example 15

To a solution of 2-acetyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]-triazine (59 mg) in tetrahydrofuran was added
15 borane-tetrahydrofuran complex (1.0 M solution in tetrahydrofuran, 1 ml) dropwise. The solution was stirred at ambient temperature for 5 hours and to the solution was added dropwise 1N-hydrochloric acid (3 ml). The solution was stirred at 80°C for 20 minutes and the tetrahydrofuran
20 was evaporated. Then, the aqueous solution was neutralized with an aqueous saturated sodium bicarbonate solution and the separated oil was extracted with dichloromethane. The extract was dried and concentrated in vacuo. The residue was purified by column
25 chromatography on silica gel and the obtained oil was crystallized from ethyl acetate to give 2-ethyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (30 ml).

mp : 144-145°C

30 NMR (CDCl₃, δ) : 1.23 (3H, t, J=7Hz), 2.88 (2H, q, J=7Hz), 3.37 (2H, t, J=6Hz), 4.25 (2H, t, J=6Hz), 6.02 (1H, s), 7.04 (2H, t, J=9Hz), 7.22 (2H, d, J=6Hz), 7.40 (2H, dd, J=6Hz and 9Hz), 8.40 (2H, d, J=6Hz)

35

Example 16

The following compounds were obtained according to a similar manner to that of Example 15.

- 5 (1) 2-(3,4-Dichlorophenyl)methyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c]-[1,2,4]triazine
mp : 188-191°C
NMR (CDCl₃, δ) : 3.40 (2H, t, J=6Hz), 3.93 (2H, s),
10 4.30 (2H, t, J=6Hz), 5.68 (1H, s), 6.99 (2H, d, J=6Hz), 7.05 (2H, t, J=9Hz), 7.20 (1H, d, J=8Hz), 7.35-7.55 (4H, m), 8.41 (2H, d, J=6Hz)
- 15 (2) 7-(4-Fluorophenyl)-2-isobutyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine
mp : 159-162°C
NMR (CDCl₃, δ) : 0.98 (6H, d, J=7Hz), 1.94 (1H, quint, J=7Hz), 2.58 (2H, d, J=7Hz), 3.32 (2H, t, J=6Hz), 4.25 (2H, t, J=6Hz), 5.58 (1H, s), 7.03
20 (2H, t, J=9Hz), 7.09 (2H, d, J=6Hz), 7.43 (2H, dd, J=6Hz and 9Hz), 8.47 (2H, d, J=6Hz)
- 25 (3) 2-Cyclopropylmethyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine
mp : 137-139°C
NMR (CDCl₃, δ) : 0.29 (2H, m), 0.56 (2H, m), 0.98 (1H, m), 2.71 (2H, d, J=7Hz), 3.42 (2H, t, J=6Hz), 4.23 (2H, t, J=6Hz), 5.95 (1H, s), 7.03 (2H, t, J=9Hz), 7.09 (2H, d, J=6Hz), 7.42 (2H, dd, J=6Hz and 9Hz), 8.50 (2H, d, J=6Hz)
- 30 (4) 2-(3,3-Dimethylbutyl)-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]-triazine
35 mp : 185°C (dec.)

NMR (CDCl₃, δ) : 0.94 (9H, s), 1.50-1.60 (2H, m),
2.75-2.85 (2H, m), 3.35 (2H, t, J=6Hz), 4.25
(2H, t, J=6Hz), 7.02 (2H, t, J=9Hz), 7.10 (2H,
d, J=6Hz), 7.43 (2H, dd, J=6Hz and 9Hz), 8.48
(2H, d, J=6Hz)

5

(5) 7-(4-Fluorophenyl)-2-neopentyl-8-(pyridin-4-yl)-
1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine
mp : 174°C (dec.)

10

NMR (CDCl₃, δ) : 1.00 (9H, s), 2.59 (2H, s), 3.30
(2H, t, J=5Hz), 4.25 (2H, t, J=5Hz), 5.70 (1H,
s), 7.03 (2H, t, J=9Hz), 7.08 (2H, d, J=6Hz),
7.43 (2H, dd, J=6Hz and 9Hz), 8.46 (2H, d,
J=6Hz)

15

(6) 2-Cyclohexylmethyl-7-(4-fluorophenyl)-8-(pyridin-4-
yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine
mp : 120-135°C (dec.)

20

NMR (CDCl₃, δ) : 0.84-1.05 (2H, m), 1.13-1.40 (4H,
m), 1.54-1.90 (5H, m), 2.60 (2H, d, J=8Hz), 3.29
(2H, t, J=6Hz), 4.24 (2H, t, J=6Hz), 5.56 (1H,
s), 7.02 (2H, t, J=9Hz), 7.08 (2H, d, J=6Hz),
7.43 (2H, dd, J=6Hz and 9Hz), 8.47 (2H, d,
J=6Hz)

25

(7) 2-(2,2-Dimethylbutyl)-7-(4-fluorophenyl)-8-(pyridin-
4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]-
triazine

mp : 148-151°C (dec.)

30

NMR (CDCl₃, δ) : 0.83 (3H, t, J=8Hz), 0.94 (6H, s),
1.36 (2H, q, J=8Hz), 2.59 (2H, s), 3.28 (2H, t,
J=6Hz), 4.25 (2H, t, J=6Hz), 5.67 (1H, s), 7.02
(2H, t, J=9Hz), 7.07 (2H, d, J=6Hz), 7.43 (2H,
dd, J=6Hz and 9Hz), 8.46 (2H, d, J=6Hz)

35

Example 17

To a mixture of 7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (89 mg) and sodium cyanoborohydride (63 mg) in methanol (1 ml) was added acetone (0.1 ml) with ice cooling. The pH of the mixture was adjusted to 3 to 4 with 1N hydrochloric acid and the solution was stirred at 4°C for 30 minutes. Then, the solution was neutralized with an aqueous saturated sodium bicarbonate solution and poured into cold water. The separated oil was extracted with ethyl acetate and the extract was washed with brine, dried and concentrated in vacuo. The residue was crystallized from diethyl ether to give 7-(4-fluorophenyl)-2-isopropyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]-triazine (75 mg).

NMR (CDCl₃, δ) : 1.20 (6H, d, J=7Hz), 3.09 (1H, m), 3.42 (2H, t, J=6Hz), 4.21 (2H, t, J=6Hz), 5.62 (1H, s), 7.03 (2H, t, J=9Hz), 7.10 (2H, d, J=6Hz), 7.42 (2H, dd, J=6Hz and 9Hz), 8.48 (2H, d, J=6Hz).

Example 18

The following compounds were obtained according to a similar manner to that of Example 17.

(1) 2-(Adamantan-2-yl)-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine
mp : 224°C (dec.)

NMR (CDCl₃, δ) : 1.47-2.18 (14H, m), 2.90 (1H, m), 3.44 (2H, t, J=6Hz), 4.18 (2H, t, J=6Hz), 5.63 (1H, s), 7.03 (2H, t, J=9Hz), 7.08 (2H, d, J=6Hz), 7.44 (2H, dd, J=6Hz and 9Hz), 8.48 (2H, d, J=6Hz)

(2) 2-Cyclohexyl-7-(4-Fluorophenyl)-8-(pyridin-4-yl)-

1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

NMR (CDCl₃, δ) : 1.10-1.40 (4H, m), 1.55-2.10 (6H, m), 2.73 (1H, m), 3.45 (2H, t, J=6Hz), 4.19 (2H, t, J=6Hz), 5.67 (1H, s), 7.03 (2H, t, J=9Hz), 7.10 (2H, d, J=6Hz), 7.42 (2H, dd, J=6Hz and 9Hz), 8.48 (2H, d, J=6Hz)

(3) 7-(4-Fluorophenyl)-8-(pyridin-4-yl)-2-(tetrahydropyran-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

NMR (CDCl₃, δ) : 1.50-1.80 (2H, m), 1.85-2.05 (2H, m), 2.98 (1H, m), 3.30-3.50 (4H, m), 3.95-4.10 (2H, m), 4.21 (2H, t, J=6Hz), 5.70 (1H, s), 7.03 (2H, t, J=9Hz), 7.09 (2H, d, J=6Hz), 7.41 (2H, dd, J=6Hz and 9Hz), 8.48 (2H, d, J=6Hz)

(4) 2-(1-Acetylpiperidin-4-yl)-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

NMR (CDCl₃, δ) : 1.52 (2H, m), 1.99 (2H, m), 2.11 (3H, s), 2.78 (1H, m), 2.98 (1H, m), 3.15 (1H, m), 3.47 (2H, t, J=6Hz), 3.85 (1H, m), 4.22 (2H, t, J=6Hz), 4.51 (1H, m), 5.69 (1H, s), 7.03 (2H, t, J=9Hz), 7.09 (2H, d, J=6Hz), 7.41 (2H, dd, J=6Hz and 9Hz), 8.47 (2H, d, J=6Hz)

(5) 7-(4-Fluorophenyl)-2-(1-methylpiperidin-4-yl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

NMR (CDCl₃:CD₃OD = 9:1, δ) : 1.50-1.75 (2H, m), 1.90-2.15 (4H, m), 2.30 (3H, s), 2.65-3.00 (3H, m), 3.46 (2H, t, J=6Hz), 4.19 (2H, t, J=6Hz), 7.07 (2H, t, J=9Hz), 7.12 (2H, d, J=6Hz), 7.39 (2H, dd, J=6Hz and 9Hz), 8.38 (2H, d, J=6Hz)

- (6) 7-(4-Fluorophenyl)-2-(1-methoxycarbonylethyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c]-[1,2,4]triazine
mp : 132-134°C
5 NMR (CDCl₃, δ) : 1.50 (3H, d, J=7Hz), 3.27-3.58 (2H, m), 3.78 (3H, s), 3.82 (1H, q, J=7Hz), 4.10-4.40 (2H, m), 6.04 (1H, s), 7.03 (2H, t, J=9Hz), 7.10 (2H, d, J=6Hz), 7.41 (2H, dd, J=6Hz and 9Hz), 8.48 (2H, d, J=6Hz)
- 10 (7) 7-(4-Fluorophenyl)-2-(indan-2-yl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine
mp : 232°C (dec.)
15 NMR (CDCl₃, δ) : 2.99-3.26 (4H, m), 3.48 (2H, t, J=6Hz), 3.90 (1H, t, J=8Hz), 4.30 (2H, t, J=6Hz), 5.68 (1H, s), 7.03 (2H, t, J=9Hz), 7.08 (2H, d, J=6Hz), 7.15-7.25 (4H, m), 7.41 (2H, dd, J=6Hz and 9Hz), 8.48 (2H, d, J=6Hz)
- 20 (8) 2-[(E)-Cinnamyl]-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine
mp : 178-183°C
25 NMR (CDCl₃, δ) : 3.43 (2H, t, J=6Hz), 3.63 (2H, d, J=6Hz), 4.27 (2H, t, J=6Hz), 5.80 (1H, br s), 6.27 (1H, td, J=6Hz and 15Hz), 6.60 (1H, d, J=15Hz), 6.98-7.09 (4H, m), 7.27-7.36 (5H, m), 7.43 (2H, dd, J=6Hz and 9Hz), 8.40 (2H, d, J=6Hz)
- 30 (9) 2-(3,3-Dimethyl-1,5-dioxaspiro[5,5]undecan-9-yl)-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine
mp : 186°C (dec.)
35 NMR (CDCl₃, δ) : 0.98 (6H, s), 1.44-1.76 (4H, m), 1.85-1.98 (2H, m), 2.15-2.28 (2H, m), 2.78-2.91

(1H, m), 3.46 (2H, t, J=6Hz), 3.52 (4H, d, J=4Hz), 4.20 (2H, t, J=6Hz), 5.60 (1H, s), 7.03 (2H, t, J=9Hz), 7.09 (2H, d, J=6Hz), 7.41 (2H, dd, J=6Hz and 9Hz), 8.46 (2H, d, J=6Hz)

5

Example 19

A mixture of 2-acetoxyacetyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]-triazine (75 mg, 0.190 mmol) and an aqueous sodium hydroxide solution (1N, 0.38 ml, 0.380 mmol) in ethanol (1.5 ml) was stirred for 30 minutes at ambient temperature. After dilution of an aqueous saturated ammonium chloride solution, the mixture was extracted with ethyl acetate. The extracts were dried over sodium sulfate, and concentrated in vacuo. The residue was purified by chromatography on silica gel (eluent: dichloromethane/methanol; 50/1-10/1), and the obtained amorphous product was crystallized from diisopropyl ether to give 7-(4-fluorophenyl)-2-hydroxyacetyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (20 mg).

mp : 133°C (dec.)

NMR (DMSO-d₆, δ) : 3.95-4.05 (2H, m), 4.10-4.20 (2H, m), 4.25 (2H, d, J=6Hz), 4.75 (1H, t, J=6Hz), 7.15 (2H, d, J=6Hz), 7.25 (2H, t, J=9Hz), 7.40 (2H, dd, J=6Hz and 9Hz), 8.50 (2H, d, J=6Hz), 8.55 (1H, s)

Example 20

A mixture of 2-(4-acetoxybenzoyl)-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]-triazine (65 mg, 0.142 mmol) and potassium carbonate (20 mg, 0.142 mmol) in methanol (1.3 ml) was stirred for 30 minutes at ambient temperature. The mixture was adjusted to pH 6 with an aqueous saturated ammonium chloride

solution, and extracted with ethyl acetate. The organic phase was washed with water and brine, dried over sodium sulfate, and concentrated in vacuo. The residue was purified by chromatography on silica gel

(eluent: dichloromethane/methanol; 30/1-20/1), and the obtained amorphous product was crystallized from diisopropyl ether to give 7-(4-fluorophenyl)-2-(4-hydroxybenzoyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (37 mg).

mp : 222°C (dec.)

NMR (CDCl₃ + CD₃OD, δ) : 4.20-4.40 (4H, m), 6.85 (2H, d, J=9Hz), 6.95-7.10 (4H, m), 7.35 (2H, dd, J=6Hz and 9Hz), 7.55 (2H, d, J=9Hz), 8.30 (2H, d, J=6Hz)

Example 21

2-tert-Butoxycarbonylaminoacetyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (50 mg) was dissolved in trifluoroacetic acid (0.5 ml). The solution was stirred at ambient temperature for 30 minutes and concentrated in vacuo. The residue was dissolved in water and the solution was neutralized with an aqueous saturated sodium bicarbonate solution. The separated oil was extracted with a mixture of dichloromethane and ethanol (7:3) and the extract was washed with water, dried and concentrated in vacuo. The residue was crystallized from ethyl acetate to give 2-aminoacetyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (30 mg).

mp : 208-211°C

NMR (DMSO-d₆, δ) : 3.50 (2H, s), 4.01 (2H, t, J=6Hz), 4.16 (2H, t, J=6Hz), 7.19 (2H, d, J=6Hz), 7.22 (2H, t, J=9Hz), 7.40 (2H, dd, J=6Hz and 9Hz), 8.49 (2H, d, J=6Hz)

Example 22

A mixture of 2-chloroacetyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]-triazine (80 mg, 0.215 mmol), morpholine (37 mg, 0.430 mmol), and triethylamine (22 mg, 0.215 mmol) in 1,2-dichloroethane (2 ml) was stirred for 24 hours at ambient temperature. After dilution of dichloromethane, the mixture was washed with an aqueous saturated sodium bicarbonate solution, and brine. The organic phase was dried over sodium sulfate, and concentrated in vacuo. The residue was purified by chromatography on silica gel (eluent: ethyl acetate-ethyl acetate/methanol; 20/1), and the obtained oil was crystallized from diisopropyl ether to give 7-(4-fluorophenyl)-2-morpholinoacetyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]-triazine (50 mg).

NMR (CDCl₃, δ) : 2.50 (4H, t, J=4.5Hz), 3.35 (2H, s), 3.65 (4H, t, J=4.5Hz), 4.20 (2H, d, J=6Hz), 4.30 (2H, d, J=6Hz), 7.05 (2H, t, J=9Hz), 7.10 (2H, d, J=6Hz), 7.40 (2H, dd, J=6Hz and 9Hz), 7.95 (1H, br s), 8.50 (2H, d, J=6Hz)

Example 23

To a mixture of 7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (118 mg) and pyridine (64 mg) in N-methyl-1-pyrrolidone (2 ml) was added phenylacetyl chloride (65 mg) under nitrogen atmosphere with ice cooling. After stirring for 1 hour at 4°C, the reaction mixture was poured into cold water. The separated oil was extracted with ethyl acetate and the extract was washed with brine, dried and concentrated in vacuo. The residue was purified by column chromatography on silica gel and the obtained oil was dissolved in 10% methanolic hydrogen chloride (1 ml). The resulting clear solution was concentrated in vacuo. The residue was

crystallized from ethyl acetate to give 7-(4-fluorophenyl)-2-phenylacetyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine hydrochloride (130 mg).

5

mp : 208-212°C

10

NMR (DMSO-d₆, δ) 3.87 (2H, s), 4.07 (2H, t, J=5Hz), 4.18 (2H, t, J=5Hz), 7.00-7.20 (5H, m), 7.29 (2H, t, J=9Hz), 7.43 (2H, dd, J=6Hz and 9Hz), 7.66 (2H, d, J=6Hz), 8.71 (2H, d, J=6Hz), 9.63 (1H, s)

Example 24

The following compounds were obtained according to a similar manner to that of Example 23.

15

(1) 7-(4-Fluorophenyl)-2-pentanoyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine hydrochloride

mp : 175°C (dec.)

20

NMR (CD₃Cl, δ) : 0.90 (3H, t, J=6Hz), 1.25-1.45 (2H, m), 1.55-1.70 (2H, m), 2.55 (2H, t, J=6Hz), 4.10-4.30 (4H, m), 7.15 (2H, t, J=9Hz), 7.40 (2H, dd, J=6Hz and 9Hz), 7.80-7.90 (2H, m), 8.10-8.25 (2H, m), 9.60 (1H, br s)

25

(2) 7-(4-Fluorophenyl)-2-isobutyryl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine hydrochloride

NMR (CDCl₃, δ) : 1.15 (6H, d, J=7Hz), 3.20-3.40 (1H, m), 4.15-4.30 (4H, m), 7.15 (2H, t, J=9Hz), 7.40 (2H, dd, J=6Hz and 9Hz), 7.80-7.90 (2H, m), 8.15-8.30 (2H, m), 9.50 (1H, br s)

30

(3) 2-(3,4-Dichlorobenzoyl)-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c]-

35

[1,2,4]triazine hydrochloride

NMR (DMSO-d₆, δ) : 4.22 (2H, t, J=6Hz); 4.33 (2H, t, J=6Hz), 7.29 (2H, t, J=9Hz), 7.40-7.60 (4H, m), 7.70 (2H, m), 7.94 (1H, s), 8.63 (2H, d, J=6Hz), 9.99 (1H, s)

(4) 7-(4-Fluorophenyl)-2-phenylglyoxyloyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine hydrochloride

mp : 182-191°C (dec.)

NMR (DMSO-d₆, δ) : 4.24 (2H, t, J=6Hz), 4.49 (2H, t, J=6Hz), 7.16 (2H, d, J=7Hz), 7.26 (2H, t, J=9Hz), 7.30-7.45 (4H, m), 7.50-7.65 (3H, m), 8.57 (2H, d, J=7Hz), 9.77 (1H, s)

(5) 7-(4-Fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydro-2-(4-trifluoromethylphenyl)glyoxyloyl-pyrazolo[5,1-c][1,2,4]triazine hydrochloride

mp : 260-265°C (dec.)

NMR (CDCl₃ + CD₃OD, δ) : 4.32-4.50 (4H, m), 7.13 (2H, t, J=9Hz), 7.30-7.43 (4H, m), 7.79 (2H, d, J=9Hz), 7.93 (2H, d, J=9Hz), 8.22 (2H, d, J=6Hz)

Example 25

To a mixture of 7-(4-fluorophenyl)-2-isobutyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (70 mg, 0.199 mmol) and pyridine (31 mg, 0.398 mmol) in N-methyl-2-pyrrolidone (1.2 ml) was added acetyl chloride (19 mg, 0.239 mmol) in N-methyl-2-pyrrolidone (0.3 ml) at ambient temperature. The reaction mixture was stirred for 1 hour, then aqueous saturated sodium bicarbonate and ethyl acetate were added thereto. The organic phase was separated, and washed with water, brine, and dried over sodium sulfate. The solvent was evaporated, and the obtained residue was purified by

column chromatography on silica gel
(eluent:dichloromethane/methanol; 100/1~40/1). The
fractions containing the object compound were concentrated
in vacuo and the obtained oil was crystallized from
diisopropyl ether to give 1-acetyl-7-(4-fluorophenyl)-2-
isobutyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo-
[5,1-c][1,2,4]triazine (57.0 mg).

mp : 194-197°C (dec.)

NMR (CDCl₃, δ) : 1.05 (3H, d, J=6Hz), 1.12 (3H, d,
J=6Hz), 1.90 (1H, m), 2.25 (3H, s), 2.57-2.69
(1H, m), 2.75-2.86 (1H, m), 3.43-3.70 (2H, m),
4.13-4.24 (1H, m), 4.33-4.50 (1H, m), 6.95-7.05
(4H, m), 7.34 (2H, dd, J=6Hz and 9Hz), 8.50 (2H,
d, J=6Hz)

Example 26

The following compounds were obtained according to a
similar manner to that of Example 1.

(1) 8-(2-Chloropyridin-4-yl)-7-(4-fluorophenyl)-1,2,3,4-
tetrahydropyrazolo[5,1-c][1,2,4]triazine

mp : 219-221°C

NMR (CDCl₃, δ) : 3.48 (2H, q, J=5Hz), 3.68 (1H, q,
J=5Hz), 4.20 (2H, t, J=5Hz), 5.65 (1H, d,
J=5Hz), 6.94 (1H, d, J=6Hz), 7.06 (2H, t,
J=9Hz), 7.16 (1H, s), 7.40 (2H, dd, J=6Hz and
9Hz), 8.20 (1H, d, J=6Hz)

(2) 8-(2-Bromopyridin-4-yl)-7-(4-fluorophenyl)-1,2,3,4-
tetrahydropyrazolo[5,1-c][1,2,4]triazine

mp : 212-216°C

NMR (CDCl₃, δ) : 3.32-3.44 (2H, m), 3.68 (1H, m),
4.20 (2H, t, J=5Hz), 5.67 (1H, br s), 6.95 (1H,
d, J=6Hz), 7.07 (2H, t, J=9Hz), 7.17 (1H, s),
7.40 (2H, dd, J=6Hz and 9Hz), 8.21 (1H, d,
J=6Hz)

- (3) 7-(4-Fluorophenyl)-8-(2-methoxypyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

mp : 205-209°C

NMR (CDCl₃:CD₃OD = 9:1, δ) : 3.35 (2H, t, J=6Hz),
3.89 (3H, s), 4.17 (2H, t, J=6Hz), 6.60 (1H, s),
6.68 (1H, d, J=6Hz), 7.05 (2H, t, J=9Hz), 7.42
(2H, dd, J=6Hz and 9Hz), 7.98 (1H, d, J=6Hz)

- (4) 7-(4-Fluorophenyl)-8-(2-fluoropyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

mp : 230-232°C

NMR (CDCl₃:CD₃OD = 9:1, δ) : 3.37 (2H, t, J=6Hz),
4.18 (2H, t, J=6Hz), 6.77 (1H, s), 6.95 (1H, d,
J=6Hz), 7.08 (2H, t, J=9Hz), 7.40 (2H, dd, J=6Hz
and 9Hz), 8.02 (1H, d, J=6Hz)

Example 27

The following compounds were obtained according to similar manners to those of Example 3, 7 and 13.

- (1) 2-Acetyl-8-(2-chloropyridin-4-yl)-7-(4-fluorophenyl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

mp : 208-209°C

NMR (CDCl₃, δ) : 2.34 (3H, s), 4.13-4.20 (2H, m),
4.20-4.31 (2H, m), 6.30 (1H, br s), 7.00-7.11
(3H, m), 7.24 (1H, s), 7.40 (2H, dd, J=6Hz and
9Hz), 8.23 (1H, d, J=6Hz)

- (2) 8-(2-Chloropyridin-4-yl)-7-(4-fluorophenyl)-2-phenylglyoxyloyl-1,2,3,4-tetrahydropyrazolo[5,1-c]-[1,2,4]triazine

NMR (CDCl₃, δ) : 4.30 (2H, t, J=5Hz), 4.45 (2H, t,
J=5Hz), 6.54-6.60 (2H, m), 6.67 (1H, s), 7.03
(2H, t, J=9Hz), 7.30 (2H, m), 7.53 (2H, t,
J=9Hz), 7.68 (1H, t, J=9Hz), 7.89-7.95 (3H, m)

- (3) 2-Acetyl-8-(2-bromopyridin-4-yl)-7-(4-fluorophenyl)-
1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine
mp : 210-211°C
5 NMR (CDCl₃, δ) : 2.35 (3H, s), 4.12-4.32 (4H, m),
6.30 (1H, br s), 7.00-7.12 (3H, m), 7.23 (1H,
s), 7.40 (2H, dd, J=6Hz and 9Hz), 8.24 (1H, d,
J=6Hz)
- (4) 8-(2-Bromopyridin-4-yl)-7-(4-fluorophenyl)-2-
10 phenylglyoxyloyl-1,2,3,4-tetrahydropyrazolo[5,1-c]-
[1,2,4]triazine
NMR (CDCl₃, δ) : 4.30 (2H, t, J=5Hz), 4.45 (2H, t,
J=5Hz), 6.53-6.61 (2H, m), 6.68 (1H, s), 7.02
15 (2H, t, J=9Hz), 7.25-7.35 (2H, m), 7.53 (2H, t,
J=9Hz), 7.66 (1H, t, J=9Hz), 7.88-7.97 (3H, m)
- (5) 7-(4-Fluorophenyl)-2-[(2-methoxyphenyl)glyoxyloyl]-8-
(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c]-
[1,2,4]triazine
20 mp : 231-245°C (dec.)
NMR (CDCl₃, δ) : 3.48 (3H, s), 4.24 (2H, t, J=6Hz),
4.43 (2H, t, J=6Hz), 6.48 (2H, d, J=6Hz), 6.77
(1H, s), 6.84 (1H, d, J=9Hz), 7.01 (2H, t,
J=9Hz), 7.15 (1H, dt, J=2Hz and 9Hz), 7.32 (2H,
25 dd, J=6Hz and 9Hz), 7.57 (1H, dt, J=2Hz and
9Hz), 8.06-8.13 (3H, m)
- (6) 2-Acetyl-7-(4-fluorophenyl)-8-(2-methoxypyridin-4-
yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine
30 mp : 148-150°C
NMR (CDCl₃:CD₃OD = 9:1, δ) : 2.28 (3H, s), 3.91 (3H,
s), 4.12 (2H, t, J=6Hz), 4.25 (2H, t, J=6Hz),
6.67 (1H, s), 6.72 (1H, d, J=6Hz), 7.06 (2H, t,
J=9Hz), 7.41 (2H, dd, J=6Hz and 9Hz), 8.02 (1H,
35 d, J=6Hz)

(7) 7-(4-Fluorophenyl)-8-(2-methoxypyridin-4-yl)-2-phenylglyoxyloyl-1,2,3,4-tetrahydropyrazolo[5,1-c]-[1,2,4]triazine

mp : 129-133°C

5 NMR (CDCl₃:CD₃OD = 9:1, δ) : 3.81 (3H, s), 4.25 (2H, t, J=6Hz), 4.42 (2H, t, J=6Hz), 6.20 (1H, s), 6.28 (1H, d, J=6Hz), 7.02 (2H, t, J=9Hz), 7.32 (2H, dd, J=6Hz and 9Hz), 7.46 (2H, t, J=8Hz), 7.61 (1H, t, J=8Hz), 7.75-7.85 (3H, m)

10

(8) 2-Acetyl-7-(4-fluorophenyl)-8-(2-fluoropyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

mp : 204-206°C

15 NMR (CDCl₃:CD₃OD = 9:1, δ) : 2.28 (3H, s), 4.14 (2H, t, J=6Hz), 4.26 (2H, t, J=6Hz), 7.02 (1H, d, J=6Hz), 7.10 (2H, t, J=9Hz), 7.04 (2H, dd, J=6Hz and 9Hz), 8.05 (1H, d, J=6Hz)

(9) 7-(4-Fluorophenyl)-8-(2-fluoropyridin-4-yl)-2-phenylglyoxyloyl-1,2,3,4-tetrahydropyrazolo[5,1-c]-[1,2,4]triazine

mp : 238-240°C

20 NMR (CDCl₃:CD₃OD = 9:1, δ) : 4.28 (2H, t, J=6Hz), 4.43 (2H, t, J=6Hz), 6.35 (1H, s), 6.60 (1H, d, J=6Hz), 7.05 (2H, t, J=9Hz), 7.48 (2H, t, J=8Hz), 7.62 (1H, t, J=8Hz), 7.75-7.90 (3H, m)

25

(10) 2-Acetyl-7-(4-fluorophenyl)-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine

hydrochloride

mp : 262-270°C (dec)

30

35 NMR (CHCl₃, δ) : 2.29 (3H, s), 4.11-4.27 (4H, m), 7.12 (2H, t, J=9Hz), 7.40 (2H, dd, J=6, 9Hz), 7.80 (2H, d, J=6Hz), 8.49 (2H, d, J=6Hz), 9.57 (1H, br s)

(11) 7-(4-Fluorophenyl)-2-phenylglyoxyloyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine
mp : 240.5-242.0°C

5 NMR (CDCl₃:CD₃OD = 9:1, δ) : 4.27 (2H, t, J=6Hz),
4.45 (2H, t, J=6Hz), 6.70 (2H, d, J=6Hz), 7.01
(2H, t, J=9Hz), 7.30 (2H, dd, J=6Hz, 9Hz), 7.47
(2H, t, J=8Hz), 7.63 (1H, t, J=8Hz), 7.81 (2H,
d, J=8Hz), 8.18 (2H, d, J=6Hz)

10 Example 28

To a suspension of 7-(4-fluorophenyl)-2-phenylglyoxyloyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (2.778 g) in a mixture of ethanol (14 ml) and ethyl acetate (10 ml) was
15 added conc. sulfuric acid (0.67 g). To the resulting clear solution was added ethyl acetate (30 ml) and the solution was stirred at ambient temperature for 4 hours. The separated solid was collected and recrystallized from aqueous acetonitrile to give 7-(4-fluorophenyl)-2-phenylglyoxyloyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine sulfate (2.7 g).
20

mp : 155-157°C


25 NMR (DMSO-d₆, δ) : 4.25 (2H, m), 4.49 (2H, m),
7.12 (2H, d, J=7Hz), 7.15-7.50 (6H, m),
7.50-7.70 (3H, m), 8.56 (2H, d, J=7Hz), 9.43
(1H, s)

30

35


C L A I M S

1. A compound of the formula :



wherein R^1 is aryl which may have suitable
substituent(s) or heterocyclic group
which may have suitable substituent(s),
15 R^2 is aryl which may have suitable
substituent(s) or heterocyclic group
which may have suitable substituent(s),
 R^3 is hydrogen or acyl,
20 R^4 is hydrogen, lower alkyl,
cyclo(lower)alkyl,
cyclo(lower)alkyl-(lower)alkyl,
carboxy(lower)alkyl, protected
carboxy(lower)alkyl, ar(lower)alkyl
which may have suitable substituent(s),
25 ar(lower)alkenyl, bridged
tricyclicalkyl, heterocyclic group
which may have suitable
substituent(s), acyl, or a group of the
formula :

30



35

(in which A is lower alkylene), and
 R^5 is hydrogen or lower alkyl,
and a pharmaceutically acceptable salt thereof.

2. A compound of claim 1, wherein

R^1 is phenyl which may have 1 to 3 suitable
substituent(s), or
pyridyl which may have 1 to 3 suitable
substituent(s),

R^2 is phenyl which may have 1 to 3 suitable
substituent(s) or
pyridyl which may have 1 to 3 suitable
substituent(s),

R^3 is hydrogen or lower alkanoyl,

R^4 is hydrogen; lower alkyl; cyclo(lower)alkyl;
cyclo(lower)alkyl-(lower)alkyl;
carboxy(lower)alkyl;
esterified carboxy(lower)alkyl;
phenyl(lower)alkyl which may have 1 to 3
suitable substituent(s); adamantanyl;
phenyl(lower)alkenyl; tetrahydropyranyl,
piperidyl or dioxaspirodecanyl, each of which
may have 1 to 3 substituent(s) selected from the
group consisting of lower alkyl and acyl; indanyl;
lower alkanoyl which may have 1 to 3 suitable
substituent(s); lower alkoxycarbonyl;
lower alkoxyglyoxyloyl; lower alkylsulfonyl;
cyclo(lower)alkylcarbonyl; aroyl which may have
1 to 3 suitable substituent(s);
ar(lower)alkanoyl which may have 1 to 3 suitable
substituent(s); ar(lower)alkenoyl;
arylthio(lower)alkanoyl; arylcarbamoyle;
aryl-thiocarbamoyle; arylglyoxyloyl which may
have 1 to 3 suitable substituent(s);
carbamoyle which may have one or two suitable
substituent(s) selected from the group
consisting of lower alkyl, hydroxy(lower)alkyl,
protected hydroxy(lower)alkyl, lower alkoxy and
cyclo(lower)alkyl; heterocycliccarbonyl;

heterocyclic(lower)alkanoyl; or
heterocycliccarbamoyl.

3. A compound of claim 2, wherein

5 R^1 is phenyl which may have 1 to 3 substituent(s)
selected from the group consisting of lower
alkyl, lower alkoxy, lower alkenyl, lower
alkynyl, mono(or di or tri)halo(lower)alkyl,
10 halogen, carboxy, protected carboxy, hydroxy,
protected hydroxy, aryl, ar(lower)alkyl,
carboxy(lower)alkyl, protected
carboxy(lower)alkyl, amino, protected amino,
di(lower)alkylamino, hydroxy(lower)alkyl,
15 protected hydroxy(lower)alkyl, nitro, acyl,
cyano, mercapto, lower alkylthio and imino; or
pyridyl which may have 1 to 3 substituent(s)
selected from the group consisting of lower
alkyl, lower alkoxy, lower alkenyl, lower
20 alkynyl, mono(or di or tri)halo(lower)alkyl,
halogen, carboxy, protected carboxy, hydroxy,
protected hydroxy, aryl, ar(lower)alkyl,
carboxy(lower)alkyl, protected
carboxy(lower)alkyl, amino, protected amino,
25 di(lower)alkylamino, hydroxy(lower)alkyl,
protected hydroxy(lower)alkyl, nitro, acyl,
cyano, mercapto, lower alkylthio and imino,
30 R^2 is phenyl which may have 1 to 3 substituent(s)
selected from the group consisting of lower
alkyl, lower alkoxy, lower alkenyl, lower
alkynyl, mono(or di or tri)halo(lower)alkyl,
35 halogen, carboxy, protected carboxy, hydroxy,
protected hydroxy, aryl, ar(lower)alkyl,
carboxy(lower)alkyl, protected
carboxy(lower)alkyl, amino, protected amino,
di(lower)alkylamino, hydroxy(lower)alkyl,

protected hydroxy(lower)alkyl, nitro, acyl, cyano, mercapto, lower alkylthio and imino; or pyridyl which may have 1 to 3 substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, lower alkenyl, lower alkynyl, mono(or di or tri)halo(lower)alkyl, halogen, carboxy, protected carboxy, hydroxy, protected hydroxy, aryl, ar(lower)alkyl, carboxy(lower)alkyl, protected

5 carboxy(lower)alkyl, amino, protected amino, di(lower)alkylamino, hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, nitro, acyl, cyano, mercapto, lower alkylthio and imino,

10 R^4 is hydrogen; lower alkyl; cyclo(lower)alkyl; cyclo(lower)alkyl-(lower)alkyl; carboxy(lower)alkyl; lower alkoxycarbonyl(lower)alkyl; phenyl(lower)alkyl which may have 1 to 3 substituent(s) selected from the group

15 consisting of halogen, lower alkyl, lower alkoxy, lower alkenyl, lower alkynyl, mono(or di or tri)halo(lower)alkyl and di(lower)alkylamino; adamantanyl; phenyl(lower)alkenyl; tetrahydropyranyl, piperidyl or

20 dioxaspirooundecanyl, each of which may have one or two substituent(s) selected from the group consisting of lower alkyl and lower alkanoyl; indanyl; lower alkanoyl which may have 1 to 3 substituent(s) selected from the group

25 consisting of carboxy, protected carboxy, lower alkoxy, halogen, protected amino, amino, hydroxy, protected hydroxy and di(lower)alkylamino; lower alkoxycarbonyl; lower alkoxyglyoxyloyl; lower alkylsulfonyl;

30 cyclo(lower)alkylcarbonyl; benzoyl which may

35

5 have 1 to 3 substituent(s) selected from the
group consisting of mono(or di or
tri)halo(lower)alkyl, halogen, protected hydroxy
and hydroxy; phenyl(lower)alkanoyl which may
have 1 to 3 substituent(s) selected from the
group consisting of lower alkoxy, aryl, halogen
and mono(or di or tri)halo(lower)alkyl;
phenyl(lower)alkenoyl;
phenylthio(lower)alkanoyl; phenylcarbamoyl;
10 phenyl-thiocarbamoyl; phenylglyoxyloyl which may
have 1 to 3 substituent(s) selected from the
group consisting of mono(or di or
tri)halo(lower)alkyl and lower alkoxy; carbamoyl
which may have one or two suitable
15 substituent(s) selected from the group
consisting of lower alkyl, hydroxy(lower)alkyl,
acyloxy(lower)alkyl, lower alkoxy and
cyclo(lower)alkyl; morpholinylcarbonyl;
indolyl(lower)alkanoyl;
20 morpholinyl(lower)alkanoyl; or
piperidylcarbamoyl.

4. A compound of claim 3, wherein
R¹ is halophenyl or pyridyl,
25 R² is halophenyl, pyridyl, halopyridyl or lower
alkoxypyridyl,
R⁴ is hydrogen; lower alkyl; cyclo(lower)alkyl;
cyclo(lower)alkyl-(lower)alkyl;
carboxy(lower)alkyl;
30 lower alkoxy carbonyl(lower)alkyl; mono(or
di)halophenyl(lower)alkyl; adamantanyl;
phenyl(lower)alkenyl; tetrahydropyranyl;
lower alkylpiperidyl; lower alkanoylpiperidyl;
di(lower)alkyldioxaspirooundecanyl; indanyl;
35 lower alkanoyl which may have a substituent

5 selected from the group consisting of carboxy, esterified carboxy, lower alkoxy, halogen, lower alkoxycarbonylamino, lower alkanoylamino, amino, hydroxy, acyloxy and di(lower)alkylamino; lower
10 alkoxycarbonyl; lower alkoxyglyoxyloyl; lower alkylsulfonyl; cyclo(lower)alkylcarbonyl; benzoyl which may have one or two substituent(s) selected from the group consisting of trihalo(lower)alkyl, halogen, acyloxy and
15 hydroxy; phenyl(lower)alkanoyl which may have one or two substituent(s) selected from the group consisting of lower alkoxy, phenyl, halogen and trihalo(lower)alkyl; phenyl(lower)alkenoyl; phenylthio(lower)alkanoyl; phenylcarbamoyle;
20 phenyl-thiocarbamoyle; phenylglyoxyloyl which may have a substituent selected from the group consisting of trihalo(lower)alkyl and lower alkoxy; carbamoyle which may have one or two suitable substituent(s) selected from the group consisting of lower alkyl, hydroxy(lower)alkyl, acyloxy(lower)alkyl, lower alkoxy and cyclo(lower)alkyl; morpholinylcarbonyl; indolyl(lower)alkanoyl;
25 morpholinyl(lower)alkanoyl; or piperidylcarbamoyle.

5. A compound of claim 4, wherein
30 R^4 is hydrogen; lower alkyl; cyclo(lower)alkyl; cyclo(lower)alkyl-(lower)alkyl; carboxy(lower)alkyl; lower alkoxycarbonyl-(lower)alkyl; mono(or di)halophenyl(lower)-alkyl; adamantanyl; phenyl(lower)alkenyl; tetrahydropyranyl; lower alkylpiperidyl;
35 lower alkanoylpiperidyl;

5 di(lower)alkyldioxaspioundecanyl; indanyl;
lower alkanoyl which may have a substituent
selected from the group consisting of carboxy,
esterified carboxy, lower alkoxy, halogen, lower
alkoxycarbonylamino, lower alkanoylamino, amino,
hydroxy, lower alkanoyloxy, cyclo(lower)-
alkylcarbonyloxy and di(lower)alkylamino;
lower alkoxycarbonyl; lower alkoxglyoxyloyl;
lower alkylsulfonyl; cyclo(lower)alkylcarbonyl;
10 benzoyl which may have one or two substituent(s)
selected from the group consisting of
trihalo(lower)alkyl, halogen, lower alkanoyloxy
and hydroxy; phenyl(lower)alkanoyl which may
have one or two substituent(s) selected from the
15 group consisting of lower alkoxy, phenyl,
halogen and trihalo(lower)alkyl;
phenyl(lower)alkenoyl;
phenylthio(lower)alkanoyl; phenylcarbamoyl;
phenyl-thiocarbamoyl; phenylglyoxyloyl which may
20 have a substituent selected from the group
consisting of trihalo(lower)alkyl and lower
alkoxy; carbamoyl which may have one or two
suitable substituent(s) selected from the group
consisting of lower alkyl, hydroxy(lower)alkyl,
25 acyloxy(lower)alkyl, lower alkoxy and
cyclo(lower)alkyl; morpholinylcarbonyl;
indolyl(lower)alkanoyl;
morpholinyl(lower)alkanoyl; or
piperidylcarbamoyl.

30

6. A compound of claim 5, wherein

 R^1 is halophenyl, R^2 is pyridyl, R^3 is hydrogen,

35


 R^4 is phenylglyoxyloyl, and

R^5 is hydrogen.

7. A compound of claim 6, which is selected from the group consisting of

- (1) 7-(4-Fluorophenyl)-2-phenylglyoxyloyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine,
- (2) 7-(4-Fluorophenyl)-2-phenylglyoxyloyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine hydrochloride, and
- (3) 7-(4-Fluorophenyl)-2-phenylglyoxyloyl-8-(pyridin-4-yl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine sulfate.


8. A process for preparing a compound of the formula :



wherein R^1 is aryl which may have suitable substituent(s) or heterocyclic group which may have suitable substituent(s),
 R^2 is aryl which may have suitable substituent(s) or heterocyclic group which may have suitable substituent(s),
 R^3 is hydrogen or acyl,
 R^4 is hydrogen, lower alkyl, cyclo(lower)alkyl, cyclo(lower)alkyl-(lower)alkyl,

carboxy(lower)alkyl, protected
 carboxy(lower)alkyl, ar(lower)alkyl
 which may have suitable substituent(s),
 ar(lower)alkenyl, bridged
 5 tricyclicalkyl, heterocyclic group
 which may have suitable
 substituent(s), acyl, or a group of the
 formula :


10



(in which A is lower alkylene), and
 R^5 is hydrogen or lower alkyl,
 or a salt thereof,
 15 which comprises

(1) subjecting a compound of the formula :


20



25

wherein R^1 , R^2 and R^5 are each as defined above,
 or a salt thereof to reduction reaction
 to give a compound of the formula :

30




35

wherein R^1 , R^2 and R^5 are each as defined above,
or a salt thereof, or

(2) subjecting a compound of the formula :


5



10

wherein R^1 , R^2 , R^3 and R^5 are each as defined above,
or a salt thereof to acylation reaction to give a
compound of the formula :

15



20

wherein R^1 , R^2 , R^3 and R^5 are each as defined above,
and
 R^4_a is acyl,
or a salt thereof, or


25

(3) subjecting a compound of the formula :

30

35

5



10


wherein R^1 , R^2 , R^3 and R^5 are each as defined above,
and

15

R^6 is hydrogen, C_1 - C_5 alkyl,
cyclo(lower)alkyl, cyclo(lower)alkyl-
(C_1 - C_5)alkyl, aryl which may have
suitable substituent(s) or
ar(C_1 - C_5)alkyl which may have suitable
substituent(s),

or a salt thereof to reduction reaction to give a
compound of the formula :

20



25

wherein R^1 , R^2 , R^3 , R^5 and R^6 are each as defined
above,


or a salt thereof, or

30

(4) subjecting a compound of the formula :

35


5



10

wherein R^1 , R^2 , R^3 and R^5 are each as defined above,
 X^{1-} is anion, and
 a group of the formula :


15



20

cyclo(lower)alkyl-(lower)alkyl,
 carboxy(lower)alkyl, protected
 carboxy(lower)alkyl, ar(lower)alkyl which
 may have suitable substituent(s),
 ar(lower)alkenyl, bridged tricyclicalkyl,
 heterocyclic group which may have suitable
 substituent(s),
 or a group of the formula :


25




30

(in which A is lower alkylene),
 or a salt thereof to reduction reaction to give a
 compound of the formula :

35




wherein R^1 , R^2 , R^3 , R^5 and a group of the formula :



are each as defined above,

or a salt thereof, or

(5) subjecting a compound of the formula :




wherein R^1 , R^2 , R^3 and R^5 are each as defined above,
and

R^4_b is acyl having protected hydroxy,
or a salt thereof to elimination reaction of the
hydroxy protective group to give a compound of the
formula :

- 103 -

5




10

wherein R^1 , R^2 , R^3 and R^5 are each as defined above,
and

R^4_c is acyl having hydroxy,
or a salt thereof, or

(6) subjecting a compound of the formula :

15




20

wherein R^1 , R^2 , R^3 and R^5 are each as defined above,
and

25

R^4_d is acyl having protected amino,
or a salt thereof to elimination reaction of the
amino protective group to give a compound of the
formula :

30



35


wherein R^1 , R^2 , R^3 and R^5 are each as defined above,
and

R_e^4 is acyl having amino,
or a salt thereof, or

5

(7) reacting a compound of the formula :

10





15

wherein R^1 , R^2 , R^3 and R^5 are each as defined above,
and


R_f^4 is acyl having a leaving group,
or a salt thereof with a compound of the formula :

20



wherein $-N$  is N-containing heterocyclic group,
or a salt thereof to give a compound of the formula :

25



30

wherein R^1 , R^2 , R^3 and R^5 are each as defined above,
and

35

R_g^4 is acyl having N-containing heterocyclic group, or salt thereof.

- 5 9. A pharmaceutical composition which comprises, as an active ingredient, a compound of claim 1 or a pharmaceutically acceptable salt thereof in admixture with pharmaceutically acceptable carriers.
- 10 10. A use of a compound of claim 1 or a pharmaceutically acceptable salt thereof as an inhibitor on the production of Interleukin-1 (IL-1) and an inhibitor on the production of tumor necrosis factor (TNF).
- 15 11. A method for the prophylactic or therapeutic treatment of Interleukin-1 (IL-1) and tumor necrosis factor (TNF) mediated diseases which comprises administering a compound of claim 1 or a pharmaceutically acceptable salt thereof to human or animals.
- 20 12. A process for preparing a pharmaceutical composition which comprises admixing a compound of claim 1 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier.
- 25

30

35

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP 94/00213A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C07D487/04 A61K31/53 //(C07D487/04,253:00,231:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,92 12154 (FUJISAWA) 23 July 1992 see claims 1,7	1,9
P,A	EP,A,0 531 901 (FUJISAWA) 17 March 1993 see claims 1,9	1,9

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

28 April 1994

Date of mailing of the international search report

- 9. 05. 94

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 94/00213

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9212154	23-07-92	JP-T- 6502178	10-03-94
EP-A-0531901	17-03-93	AU-A- 2280592	11-03-93